<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5438173</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0178011</article-id><article-id pub-id-type="publisher-id">PONE-D-16-48043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject><subj-group><subject>Mesenchymal Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Neurons</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cellular Neuroscience</subject><subj-group><subject>Neurons</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Antioxidants</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Neurons</subject><subj-group><subject>Nerve Fibers</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cellular Neuroscience</subject><subj-group><subject>Neurons</subject><subj-group><subject>Nerve Fibers</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Processes</subject><subj-group><subject>Cell Death</subject><subj-group><subject>Apoptosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Processes</subject><subj-group><subject>Cell Death</subject><subj-group><subject>Neuronal Death</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuronal Tuning</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy</article-title><alt-title alt-title-type="running-head">MSC preconditioning increases the secretion of trophic factors relevant for DN treatment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oses</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Olivares</surname><given-names>Bel&#x000e9;n</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ezquer</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Acosta</surname><given-names>Cristian</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bosch</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Donoso</surname><given-names>Macarena</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>L&#x000e9;niz</surname><given-names>Patricio</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7696-4215</contrib-id><name><surname>Ezquer</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Centro de Medicina Regenerativa, Facultad de Medicina Cl&#x000ed;nica Alemana-Universidad del Desarrollo. Av. Las Condes, Santiago, Chile</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Centro de Qu&#x000ed;mica M&#x000e9;dica, Facultad de Medicina Cl&#x000ed;nica Alemana-Universidad del Desarrollo. Av. Las Condes, Santiago, Chile</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Instituto de Histolog&#x000ed;a y Embriolog&#x000ed;a de Mendoza (IHEM-CONICET), Facultad de Medicina, Universidad Nacional de Cuyo, Mendoza, Argentina</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Facultad de Ingenier&#x000ed;a, Universidad del Desarrollo. Av. Plaza, Santiago, Chile</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Unidad de Cirug&#x000ed;a Pl&#x000e1;stica, Reparadora y Est&#x000e9;tica, Cl&#x000ed;nica Alemana. Av. Vitacura, Santiago, Chile</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kirchmair</surname><given-names>Rudolf</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Medical University Innsbruck, AUSTRIA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> CO FE.</p></list-item><list-item><p><bold>Data curation:</bold> CO BO ME PL FE CA.</p></list-item><list-item><p><bold>Formal analysis:</bold> CO PB MD BO FE CA.</p></list-item><list-item><p><bold>Funding acquisition:</bold> FE ME.</p></list-item><list-item><p><bold>Investigation:</bold> CO BO FE CA.</p></list-item><list-item><p><bold>Methodology:</bold> CO ME PB MD PL CA.</p></list-item><list-item><p><bold>Project administration:</bold> FE.</p></list-item><list-item><p><bold>Resources:</bold> PL FE.</p></list-item><list-item><p><bold>Supervision:</bold> FE.</p></list-item><list-item><p><bold>Visualization:</bold> FE.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> CO FE.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> CO BO ME PB MD PL FE CA.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>eezquer@udd.cl</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>5</issue><elocation-id>e0178011</elocation-id><history><date date-type="received"><day>5</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Oses et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Oses et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0178011.pdf"/><abstract><p>Diabetic neuropathy (DN) is one of the most frequent and troublesome complications of diabetes mellitus. Evidence from diabetic animal models and diabetic patients suggests that reduced availability of neuroprotective and pro-angiogenic factors in the nerves in combination with a chronic pro-inflammatory microenvironment and high level of oxidative stress, contribute to the pathogenesis of DN. Mesenchymal stem cells (MSCs) are of great interest as therapeutic agents for regenerative purposes, since they can secrete a broad range of cytoprotective and anti-inflammatory factors. Therefore, the use of the MSC secretome may represent a promising approach for DN treatment. Recent data indicate that the paracrine potential of MSCs could be boosted by preconditioning these cells with an environmental or pharmacological stimulus, enhancing their therapeutic efficacy. In the present study, we observed that the preconditioning of human adipose tissue-derived MSCs (AD-MSCs) with 150&#x003bc;M or 400&#x003bc;M of the iron chelator deferoxamine (DFX) for 48 hours, increased the abundance of the hypoxia inducible factor 1 alpha (HIF-1&#x003b1;) in a concentration dependent manner, without affecting MSC morphology and survival. Activation of HIF-1&#x003b1; led to the up-regulation of the mRNA levels of pro-angiogenic factors like vascular endothelial growth factor alpha and angiopoietin 1. Furthermore this preconditioning increased the expression of potent neuroprotective factors, including nerve growth factor, glial cell-derived neurotrophic factor and neurotrophin-3, and cytokines with anti-inflammatory activity like IL4 and IL5. Additionally, we observed that these molecules, which could also be used as therapeutics, were also increased in the secretome of MSCs preconditioned with DFX compared to the secretome obtained from non-preconditioned cells. Moreover, DFX preconditioning significantly increased the total antioxidant capacity of the MSC secretome and they showed neuroprotective effects when evaluated in an in vitro model of DN. Altogether, our findings suggest that DFX preconditioning of AD-MSCs improves their therapeutic potential and should be considered as a potential strategy for the generation of new alternatives for DN treatment.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Proyecto Interfacultades UDD</institution></funding-source><award-id>CIF16-UDD</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7696-4215</contrib-id><name><surname>Ezquer</surname><given-names>Fernando</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Proyecto FONDECYT</institution></funding-source><award-id>1170712</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7696-4215</contrib-id><name><surname>Ezquer</surname><given-names>Fernando</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the CIF-16 UDD grant and FONDECYT 1170712 grant awarded to Dr. Fernando Ezquer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="1"/><page-count count="22"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The incidence of diabetes mellitus (DM) is growing and reaching epidemic proportions with more than 260 million patients worldwide [<xref rid="pone.0178011.ref001" ref-type="bibr">1</xref>]. The most frequent and earliest complication associated to diabetes mellitus is diabetic neuropathy (DN), affecting 60% of type 1 and type 2 DM patients [<xref rid="pone.0178011.ref002" ref-type="bibr">2</xref>]. DN can affect sensory, motor or autonomic nerve fibers in any part of the body. However, the most common form is the distal symmetry sensory-motor neuropathy, affecting the lower extremities [<xref rid="pone.0178011.ref003" ref-type="bibr">3</xref>]. Patients afflicted with DN perceive a significant reduction in quality of life, due to the loss of sensation in different areas of the body, chronic pain and recurrent ulcerations caused by an impaired pain response, and a reduced blood flow to the affected areas [<xref rid="pone.0178011.ref004" ref-type="bibr">4</xref>]. These ulcerations often develop gangrenous infections leading to the amputation of the affected limb [<xref rid="pone.0178011.ref004" ref-type="bibr">4</xref>]. Thus, DN is responsible for 20% of the hospitalizations of DM patients and is the second leading cause of amputation worldwide, exceeded only by amputations caused by accidental trauma [<xref rid="pone.0178011.ref005" ref-type="bibr">5</xref>].</p><p>Although DN is clearly a multifactorial disease, the specific mechanisms that contribute to DN onset and progression are not completely understood. However, the increment of reactive oxygen species (ROS) caused by exacerbated glucose metabolism appears to be the main mechanism responsible for nerve fiber degeneration [<xref rid="pone.0178011.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0178011.ref007" ref-type="bibr">7</xref>]. Increased ROS levels induce: i) apoptosis of neurons and Schwann cells with a concomitant reduction in the local levels of several neuroprotective factors; ii) reduction in the local blood flow to nerve fibers and a decline in the angiogenic process; and iii) a chronic pro-inflammatory microenvironment [<xref rid="pone.0178011.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0178011.ref007" ref-type="bibr">7</xref>]. Therefore, reduced local levels of neuroprotective, pro-angiogenic and anti-inflammatory factors clearly correlate with the onset and progression of DN [<xref rid="pone.0178011.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0178011.ref009" ref-type="bibr">9</xref>].</p><p>Despite the continued increased incidence of DM, there is no effective clinical treatment focused on the mechanisms that lead to the development of DN. All current clinical treatments are limited to controlling blood glucose levels and to relieving symptomatic pain [<xref rid="pone.0178011.ref010" ref-type="bibr">10</xref>]. Therefore, more effective therapies are needed to improve nerve function in patients with DN.</p><p>Recently, it has been proposed that the use of stem cells could be a promising therapeutic strategy for the management of complex diseases like DN since unlike conventional pharmacological treatments, stem cells may act through multiple mechanisms [<xref rid="pone.0178011.ref011" ref-type="bibr">11</xref>]. Among different types of adult stem cells, mesenchymal stem cells (MSCs) have several comparative advantages that make them a very attractive candidate for the treatment of DN. MSCs can: i) easily be isolated from different tissues including bone marrow, umbilical cord blood and adipose tissue and can be highly expanded <italic>in vitro</italic> [<xref rid="pone.0178011.ref012" ref-type="bibr">12</xref>]; ii) exhibit cellular plasticity, so in theory they could differentiate into neurons and Schwann cells [<xref rid="pone.0178011.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0178011.ref014" ref-type="bibr">14</xref>]; iii) produce high levels of trophic cues including neuroprotective and pro-angiogenic factors [<xref rid="pone.0178011.ref015" ref-type="bibr">15</xref>]; iv) are able to reduce high levels of oxidative stress [<xref rid="pone.0178011.ref016" ref-type="bibr">16</xref>]; and v) are defined as immunomodulatory cells. Thus, by producing anti-inflammatory molecules they could reduce chronic inflammatory processes [<xref rid="pone.0178011.ref017" ref-type="bibr">17</xref>]. These properties have led researchers to evaluate the role of local administration of MSCs in animal models of DM as a therapeutic option for DN treatment. It has been reported that unilateral intramuscular administration of MSCs in diabetic animals induces a partial recovery of motor and sensory nerve conduction velocity, a restoration of normal structure of nerve fibers, and an increased blood flow to damaged nerves only in the transplanted side compared to the vehicle treated side [<xref rid="pone.0178011.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0178011.ref020" ref-type="bibr">20</xref>]. Furthermore, authors reported an increased in the levels of several trophic factors, including beta-fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), nerve growth factor (NGF), and neurotrophin-3 (NT3) in the periphery of nerves [<xref rid="pone.0178011.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0178011.ref020" ref-type="bibr">20</xref>]. These data, added to the lack of differentiation of MSCs into neurons or Schwann cells, suggest that the therapeutic effect observed is mainly related to the secretion of paracrine molecules by MSCs, which enables the recovery of normal levels of angiogenic and neurotrophic factors [<xref rid="pone.0178011.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0178011.ref020" ref-type="bibr">20</xref>].</p><p>It is well known that once in the damaged tissue, MSCs are able to sense the microenvironment and change the pattern of secreted biomolecules according to the special needs of the damaged tissue [<xref rid="pone.0178011.ref021" ref-type="bibr">21</xref>]. Recently, it has been reported that this response could also be achieved <italic>in vitro</italic> by subjecting MSCs to a preconditioning stimulus, leading to the modulation of their paracrine action [<xref rid="pone.0178011.ref022" ref-type="bibr">22</xref>]. The preconditioning process generally consists of incubating these cells with a toxic agent at a sub-lethal concentration. This process leads to the up-regulation of expression and secretion of several molecules that are needed to reduce damage. In this sense, it has been reported that preconditioning of MSCs with hypoxia or with reactive oxygen species (ROS) inducing agents stimulates the secretion of high levels of pro-angiogenic and anti-apoptotic factors [<xref rid="pone.0178011.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0178011.ref025" ref-type="bibr">25</xref>]. Moreover, lipopolysaccharide or interferon gamma preconditioning induces the secretion of molecules with anti-inflammatory activity [<xref rid="pone.0178011.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0178011.ref027" ref-type="bibr">27</xref>]. Accordingly, this kind of strategy could be used to induce the production and secretion of an appropriate combination and ratio of trophic factors specific for a determined pathology, thus enhancing the effectiveness of the therapy.</p><p>Our work aimed to evaluate whether the <italic>in vitro</italic> preconditioning of adipose tissue-derived MSCs (AD-MSCs) with the iron chelator deferoxamine (DFX), a hypoxia mimetic agent with antioxidant properties, was able to increase the production and secretion of pro-angiogenic, neuroprotective, and anti-inflammatory molecules relevant for the clinical management of DN.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Isolation, expansion and characterization of AD-MSCs</title><p>Human AD-MSCs were isolated from freshly subcutaneous adipose tissue samples (abdominal region) obtained from liposuction aspirates of four patients undergoing cosmetic liposuction at Cl&#x000ed;nica Alemana, Santiago, Chile after obtaining written informed consent. Donors were female between 22 and 56 years of age and with a body mass index (BMI) of 25 &#x000b1; 1 (Mean &#x000b1; SEM). All used protocols were approved by the Ethics Committee of Facultad de Medicina Cl&#x000ed;nica Alemana-Universidad del Desarrollo.</p><p>For MSC isolation, 200ml aliquots of fat were washed twice with equal volume of phosphate-buffered saline (PBS) and cut into small pieces. Samples were digested with 3mg/ml collagenase type II (Gibco, Grand Island, NY) in PBS and incubated 30 minutes at 37&#x000b0;C. At the end of digestion, 10% fetal bovine serum (FBS) (Gibco, Auckland, NZ) was added to neutralize collagenase. The mixture was then centrifuged at 400 g for 10 minutes to remove floating adipocytes. Pellets were re-suspended in &#x003b1;-minimum essential medium (&#x003b1;-MEM) (Gibco, Auckland, NZ) supplemented with 10% FBS and 0.16mg/ml gentamicin (Sanderson Laboratory, Santiago, Chile). Cells were plated at a density of 7000 cells/cm<sup>2</sup> and cultured at 37&#x000b0;C in a 5% CO<sub>2</sub> atmosphere. When cells reached 90% confluency, they were detached with 0.25% trypsin, 2.65mM EDTA (Sigma-Aldrich, St. Louis, MO), centrifuged and subcultured at 7000 cells/cm<sup>2</sup>. After two subcultures, cells were characterized according to their adipogenic and osteogenic differentiation potential. For this, MSCs were incubated with adipogenic differentiation media consisting of &#x003b1;-MEM supplemented with 10% FBS, 1&#x003bc;M dexamethasone (Sigma-Aldrich) and 10&#x003bc;M rosiglitazone (Cayman Chemicals, Ann Arbor, MI) for 15 days or osteogenic differentiation media composed by &#x003b1;-MEM supplemented with 10% FBS, 0.1&#x003bc;M dexamethasone, 50&#x003bc;g/ml ascorbate-2-phosphate (Sigma-Aldrich) and 10mM beta-glycerol phosphate (Sigma-Aldrich) for 21 days. In both cases, medium containing differentiation stimuli was replaced every three days. To evaluate adipogenic potential, cultures were stained with Oil Red-O (Sigma-Aldrich). To evaluate osteogenic potential, cultures were fixed with 10% ethanol and stained with Alizarin Red-S (Sigma-Aldrich) as previously described [<xref rid="pone.0178011.ref021" ref-type="bibr">21</xref>].</p><p>Immunophenotyping was performed by flow cytometry analysis after immunostaining with monoclonal antibodies against putative human MSC markers CD29 (FITC-conjugated, clone TS2/16), CD13 (FITC-conjugated, clone WM-15), CD105 (PE-conjugated, clone SN6), CD73 (PE-conjugated, clone AD2), and CD90 (PE-conjugated, clone 5E10), or characteristic markers of other cell lineages: CD235a (APC-conjugated, clone HIR2), CD31 (APC-conjugated, clone WM-59), and CD45 (APC-conjugated, clone 2D1) as previously described [<xref rid="pone.0178011.ref028" ref-type="bibr">28</xref>]. All antibodies were purchased from eBioscience (San Diego, CA).</p></sec><sec id="sec004"><title>MSC preconditioning with DFX and determination of cell viability</title><p>MSCs (passage 3) at 70% confluency were incubated for 48 hours in &#x003b1;-MEM without FBS and supplemented with 150&#x003bc;M DFX (Sigma-Aldrich), 400&#x003bc;M DFX or double distilled water (vehicle) as a negative control. After preconditioning, cells were trypsinized and the number of living cells was estimated with trypan blue solution dye test. Briefly, a 1:1 dilution of trypan blue solution (Sigma-Aldrich) with cell suspension was used. Then 10&#x003bc;l of the mixed suspension was loaded into a hemocytometer, and the number of viable cells was determined under a phase contrast microscope.</p></sec><sec id="sec005"><title>Purification of MSC secretome</title><p>After the incubation of MSCs with DFX or vehicle, the MSC secretomes were obtained by harvesting the culture media. The media were centrifuged at 400 g for 10 minutes to remove whole cells, and concentrated 10 times (v/v) using 3 kDa cutoff filters (Millipore, Midlesex, MA). In order to completely eliminate DFX from the secretome, the concentrates were washed twice with 15ml of PBS and re-concentrated again with the same filters and frozen at -80&#x000b0;C until use.</p></sec><sec id="sec006"><title>Quantification of HIF-1&#x003b1; levels</title><p>After preconditioning with DFX, MSCs were trypsinized and lysated with cell lysis buffer containing protease inhibitor cocktail (Thermo, Waltham, MA). HIF-1&#x003b1; abundance was evaluated in cell lysates using the human HIF-1&#x003b1; ELISA kit (Abcam, Cambridge, UK), following manufacturer`s instructions. Data were normalized per mg of protein present in each sample using the BCA protein assay kit (Thermo). Data were presented as fold change in preconditioned <italic>versus</italic> non-preconditioned cells.</p></sec><sec id="sec007"><title>Quantification of mRNA levels of pro-angiogenic, neuroprotective and anti-inflammatory factors</title><p>After preconditioning with DFX, total RNA was purified using Trizol (Invitrogen, Grand Island, NY) following manufacture`s instructions. Two micrograms of total RNA were used to perform reverse transcription with MMLV reverse transcriptase (Invitrogen) and oligo dT primers. Real time PCR reactions were performed in a 10&#x003bc;l final volume containing: 50ng cDNA, PCR LightCycler-DNA Master SYBERGreen reaction mix (Roche, Indianapolis, IN), 3mM MgCl<sub>2</sub> and 0.5&#x003bc;M of the primers to amplify the pro-angiogenic factors VEGF&#x003b1;, bFGF, Angiopoietin-1 (ANG-1), and platelet-derived growth factor (PDGF); the neuroprotective factors NGF, NT3, glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) and the anti-inflammatory factors IL4, IL5, IL10 and tumor necrosis factor stimulated gene 6 (TSG6) (<xref ref-type="table" rid="pone.0178011.t001">Table 1</xref>), using a Light-Cycler 1.5 thermocycler (Roche). To ensure that amplicons were generated from mRNA and not from genomic DNA, controls without reverse transcriptase during the reverse transcription reaction were included. Analysis of melting curve was used to ensure that only one product was amplified during the reaction. Agarose gel electrophoresis was used to characterize amplicon sizes. Relative quantifications were performed by the &#x00394;&#x00394;CT method [<xref rid="pone.0178011.ref021" ref-type="bibr">21</xref>]. The mRNA level of each target gene was normalized against the mRNA levels of the housekeeping genes elongation factor 1 alpha 1 (EEF1A1) and ribosomal protein L13A (RPL13A) of the same sample. Data were presented as fold change of gene expression in preconditioned <italic>versus</italic> non-preconditioned cells.</p><table-wrap id="pone.0178011.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.t001</object-id><label>Table 1</label><caption><title>Specific primers for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) amplification.</title></caption><alternatives><graphic id="pone.0178011.t001g" xlink:href="pone.0178011.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Gen</th><th align="center" rowspan="1" colspan="1">Primer Foward</th><th align="center" rowspan="1" colspan="1">Primer Reverse</th><th align="center" rowspan="1" colspan="1">Amplicon size</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">EEF1A1</td><td align="center" rowspan="1" colspan="1"><monospace>AAGGATGTTCGTCGTGGCAA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>GCGCTTATTTGGCCTGGATG</monospace></td><td align="center" rowspan="1" colspan="1">113 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">RPL13a</td><td align="center" rowspan="1" colspan="1"><monospace>CGTGCGTCTGAAGCCTACAA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>TGTCACTGCCTGGTACTTCC</monospace></td><td align="center" rowspan="1" colspan="1">82 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">VEGF&#x003b1;</td><td align="center" rowspan="1" colspan="1"><monospace>TTCCAGGAGTACCCTGATGAGATCGAG</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>TGATCCGCATAATCTGCATGGTGATGT</monospace></td><td align="center" rowspan="1" colspan="1">145 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">ANG1</td><td align="center" rowspan="1" colspan="1"><monospace>CTTGTGGCCCCTCCAATCTAA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>GGCCCTTTGAAGTAGTGCCA</monospace></td><td align="center" rowspan="1" colspan="1">94 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">bFGF</td><td align="center" rowspan="1" colspan="1"><monospace>CCGGTCAAGGAAATACACCAGT</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>TATAGCTTTCTGCCCAGGTCCTGT</monospace></td><td align="center" rowspan="1" colspan="1">94 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">PDGF</td><td align="center" rowspan="1" colspan="1"><monospace>GGACTGCGTTGGTGATGTAA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>GGACAAGCACCACATTTCCAG</monospace></td><td align="center" rowspan="1" colspan="1">141 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">GDNF</td><td align="center" rowspan="1" colspan="1"><monospace>TGACTTGGGTCTGGGCTATGAAAC</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>TCGTACGTTGTCTCAGCTGCAT</monospace></td><td align="center" rowspan="1" colspan="1">87 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">NGF</td><td align="center" rowspan="1" colspan="1"><monospace>TCCAAGTCGCTGCCTTTGCATA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>ATAGGCATCCCATCAGCCTCATTG</monospace></td><td align="center" rowspan="1" colspan="1">91 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">NT3</td><td align="center" rowspan="1" colspan="1"><monospace>GAAACGCGATGTAAGGAAGCCA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>GGACGTAGGTTTGGGATGTTTTGC</monospace></td><td align="center" rowspan="1" colspan="1">100 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">BDNF</td><td align="center" rowspan="1" colspan="1"><monospace>CCAGAAAGTTCGGCCCAATGAAGA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>AGGCTCCAAAGGCACTTGACTA</monospace></td><td align="center" rowspan="1" colspan="1">91 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">CNTF</td><td align="center" rowspan="1" colspan="1"><monospace>TCCAAGTCGCTGCCTTTGCATA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>ATAGGCATCCCATCAGCCTCATTG</monospace></td><td align="center" rowspan="1" colspan="1">91 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">IL4</td><td align="center" rowspan="1" colspan="1"><monospace>GCAGCTGATCCGATTCCTGAAA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>TTCCAACGTACTCTGGTTGGCT</monospace></td><td align="center" rowspan="1" colspan="1">100 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">IL5</td><td align="center" rowspan="1" colspan="1"><monospace>ACCTTGGCACTGCTTTCTACT</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>CCCCTTGCACAGTTTGACTC</monospace></td><td align="center" rowspan="1" colspan="1">148 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">IL10</td><td align="center" rowspan="1" colspan="1"><monospace>TACGGCGCTGTCATCGATTT</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>CACTCATGGCTTTGTAGATGCCTT</monospace></td><td align="center" rowspan="1" colspan="1">111 bp</td></tr><tr><td align="center" rowspan="1" colspan="1">TSG-6</td><td align="center" rowspan="1" colspan="1"><monospace>AGCACGGTCTGGCAAATACA</monospace></td><td align="center" rowspan="1" colspan="1"><monospace>ATCCATCCAGCAGCACAGAC</monospace></td><td align="center" rowspan="1" colspan="1">138 bp</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec008"><title>Quantification of protein levels of pro-angiogenic, neuroprotective and anti-inflammatory factors</title><p>After preconditioning, VEGF-&#x003b1;, NGF, and IL4 levels were measured in the MSC secretomes using the human VEGF-&#x003b1; ELISA kit (eBioscience); human beta-NGF ELISA kit (RayBiotech); and human IL4 high sensitivity ELISA kit (eBioscience), respectively.</p></sec><sec id="sec009"><title>Determination of total antioxidant capacity of MSC secretomes</title><p>Total antioxidant capacity was determined in reaction volumes of 50&#x003b1;l of MSC secretomes using the Antioxidant Assay kit (Cayman Chemical) following manufacturer`s instructions. Results were presented as fold change in secretomes of preconditioned <italic>versus</italic> non-preconditioned cells.</p></sec><sec id="sec010"><title>Detection of DFX in MSC secretomes</title><p>Presence of DFX in the MSC secretomes was evaluated by High Performance Liquid Chromatography (HPLC) based on a modified method reported by DeFrancia et al. [<xref rid="pone.0178011.ref029" ref-type="bibr">29</xref>]. A VWR Hitachi LaChromElite chromatographic system equipped with autosampler, column oven adjusted to 25&#x000b0;C, and a UV-DAD detector adjusted to 430nm was used. In order to prevent metal interference, the entire system was previously purged with a 20mM EDTA solution (Sigma-Aldrich). Deferoxamine was evaluated in samples of the MSC secretome before the washing steps and after the first and second washing steps. For this, 50&#x003bc;l of each sample were first complexed with 50&#x003bc;l of a 3mM ferric chloride solution (Sigma-Aldrich). Samples were incubated for 5 minutes to obtain the ferroxamine form and 5&#x003bc;l of this solution were injected into the chromatographic system with a mobile phase consisting of 15% methanol in an aqueous solution containing 0,5% triethylamine adjusted to pH 8.3. Samples were separated on a Kromasil&#x000ae; C18 column (4,6 x 100 mm) with 3.5&#x003bc;m particle size through a flow rate of 0.8ml/min. Signals were quantified using a six point DFX standard calibration curve from 10&#x003bc;M to 2000&#x003bc;M (r<sup>2</sup> 0.998).</p></sec><sec id="sec011"><title>Isolation and culture of dorsal root ganglion (DGR) neurons</title><p>DRG neurons were harvested from Wistar rats at embryonic day 15 (E15). All procedures were approved by the Institutional Animal Care and Use Committee of the School of Medical Sciences, UNCuyo (Argentina).</p><p>Embryos at E15 were obtained from terminally anaesthetized (80mg/kg pentobarbitone i.p.) pregnant rats. A total of 8 embryos from 2 litters were used in these experiments. E15 DRG neurons were cultured following previously published protocols [<xref rid="pone.0178011.ref030" ref-type="bibr">30</xref>]. Briefly, DRGs from all levels were dissected and enzymatically digested (0.25% trypsin in Ca<sup>2+</sup> and Mg<sup>2+</sup>-free HBSS for 10 minutes followed by 0.25% collagenase for 10 minutes in standard DMEM at 37&#x000b0;C). Enzymatic reaction was stopped by addition of DMEM supplemented with 10% FBS. The ganglia were then centrifuged for 3 minutes at 600 g, the supernatant discarded and the tissue resuspended in DMEM/F12 (Gibco) supplemented with 10% FBS. The tissue was then mechanically dissociated and plated onto round coverslips (Bellco Glass, Germany), coated with 10ng/mm<sup>2</sup> poly-D-Lysine (Sigma-Aldrich) and 1ng/mm<sup>2</sup> laminin (Sigma-Aldrich). Neurons were kept at 37&#x000b0;C and 5% CO<sub>2</sub> in DMEM/F12 with 10% FBS. Cell density at plating was 2x10<sup>5</sup> neurons/ml. All neurons were cultured in presence of 10ng/ml mouse NGF 7S (Alomone Labs, Israel). 24 hours after plating, culture media was replaced with N2 medium (ThermoFisher, Waltham, MA) supplemented with NGF 7S. Culture medium supplemented with NGF was replaced daily.</p></sec><sec id="sec012"><title>Incubation with MSC secretomes and apoptosis assay</title><p>Apoptosis was determined on DGR neurons on the 3<sup>rd</sup> day. For this, culture media were supplemented with: i) the secretome obtained form the preconditioning of 8x10<sup>5</sup> MSCs with 150&#x003bc;M DFX; ii) the secretome obtained form the preconditioning of 8x10<sup>5</sup> MSCs with 400&#x003bc;M DFX; iii) the secretome obtained form 8x10<sup>5</sup> non-preconditioned MSCs or iv) the vehicle. Culture medium contains a basal 25mM glucose that is essential for DRG neuron culture. To produce a hyperglycemic insult, 20mM additional glucose (yielding a total of 45mM glucose) was added to the medium 4 hours after supplementation with the secretomes and maintained for 24 hours.</p><p>To determine the percentage of apoptotic cells, DRG neurons were fixed with 4% paraformaldehyde (Merck) and evaluated for apoptosis by the in situ TdT-mediated dUPT nick end labeling (TUNEL) assay with an in situ cell death detection kit (Promega, Madison, WI) following manufacturer&#x02019;s instructions. Cells were counterstained with 4&#x02019;-6&#x02019;-diamidino-2-phenylindole (DAPI) (Invitrogen). Cells treated with DNAse I (Fermentas, Burlinton, Canada) were considered as positive controls. Cells treated with reaction solution but without terminal transferase were considered as negative controls. DRG neurons were examined using a Fluoview FV10i confocal microscope (Olympus, Tokyo, Japan). More than 2500 DGR neurons were examined for each condition. Data were analyzed with the Olympus FV10-ASW4.1 software. Results were presented as percentages of apoptotic cells.</p></sec><sec id="sec013"><title>Statistical analysis</title><p>Data were presented as mean &#x000b1; standart error of the mean (SEM). Multiple group comparisons were performed by analysis of variance (ANOVA) followed by Bonferroni <italic>post hoc test</italic>, while comparisons between two experimental groups were performed by Student&#x02019;s <italic>t</italic> test. <italic>p</italic>&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>Characterization of human AD-MSCs</title><p>Human AD-MSCs were isolated from subcutaneous adipose tissue samples obtained from liposuction aspirates of four female patients undergoing cosmetic liposuction. Five days after plating, MSCs demonstrated the characteristic long spindle-shaped morphology (<xref ref-type="fig" rid="pone.0178011.g001">Fig 1A</xref>), and exhibited adipogenic and osteogenic differentiation when they were stimulated with the appropriate differentiation media (<xref ref-type="fig" rid="pone.0178011.g001">Fig 1B</xref>). Additionally, cells at passage three were characterized according to the presence of putative human MSC surface markers and absence of surface markers characteristic of other cell lineages. Flow cytometry analysis showed that AD-MSCs were more than 98% positive for CD29, CD13, CD105, CD73, and CD90, and less than 1% positive for CD235a, CD31 and CD45 (<xref ref-type="fig" rid="pone.0178011.g001">Fig 1C</xref>), indicating that the isolated cells had the typical MSC phenotype.</p><fig id="pone.0178011.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g001</object-id><label>Fig 1</label><caption><title>Characterization of human AD-MSCs.</title><p>(A) Morphological characteristics of MSCs five days after plating. (B) Representative images of AD-MSCs at passage three, differentiated towards adipogenic and osteogenic lineages. Lipids droplets were stained with Oil red-O whereas hydroxyapatite precipitates were stained with alizarin red. (C) Flow cytometry analysis of AD-MSCs at passage three, for putative human MSC markers (CD29, CD13, CD105, CD73 and CD90) and markers characteristic of other cell lineages (CD235a, CD31 and CD45). Grey histograms represent isotype controls while black histograms represent specific antibodies. Data shown are representative of MSCs isolated from four different donors. Experiments were repeated three times at technical level.</p></caption><graphic xlink:href="pone.0178011.g001"/></fig></sec><sec id="sec016"><title>Deferoxamine preconditioning increases HIF-1&#x003b1; abundance without affecting MSC morphology and survival</title><p>AD-MSCs were incubated with 150&#x003bc;M or 400&#x003bc;M of the hypoxic mimetic agent DFX or with the vehicle (non-preconditioned cells). We chose these doses of DFX since it has been previously reported that, for others stem cells types, the incubation with this dose range improves their therapeutic potential and has only a modest impact on stem cells survival [<xref rid="pone.0178011.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0178011.ref032" ref-type="bibr">32</xref>]. We observed that 48 hours of preconditioning did not induce cell morphology changes (<xref ref-type="fig" rid="pone.0178011.g002">Fig 2A</xref>) and did not significantly reduce cell survival (<xref ref-type="fig" rid="pone.0178011.g002">Fig 2B</xref>) (6.82x10<sup>5</sup> &#x000b1; 0.20x10<sup>5</sup> cells after preconditioning with 150&#x003bc;M DFX; 6.83x10<sup>5</sup> &#x000b1; 0.22x10<sup>5</sup> cells after preconditioning with 400&#x003bc;M DFX compared to 7.95x10<sup>5</sup> &#x000b1; 0.43x10<sup>5</sup> cells in the non-preconditioned condition), suggesting that 48 hours of preconditioning with 150&#x003bc;M or 400&#x003bc;M of DFX have nontoxic effects on MSCs.</p><fig id="pone.0178011.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g002</object-id><label>Fig 2</label><caption><title>Deferoxamine preconditioning increases HIF-1&#x003b1; abundance without affecting MSC morphology and survival.</title><p>(A) Morphological characteristics of MSCs exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours. (B) Quantification of MSC survival determined by trypan blue exclusion assay for cells exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours. Data is presented as number of living cells. (C) Quantification of HIF-1&#x003b1; protein levels in lysates of MSCs exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours. Data were expressed as fold change in preconditioned versus non-preconditioned cells. Quantitative data correspond to mean &#x000b1; SEM. N = 4 per experimental group (biological repeats). Experiments were repeated three times at technical level. * <italic>p&#x0003c; 0.05</italic>.</p></caption><graphic xlink:href="pone.0178011.g002"/></fig><p>HIF-1&#x003b1; has been described as the main hypoxia marker. We observed that MSC preconditioning for 48 hours with DFX induced a dose-dependent increase in HIF-1&#x003b1; abundance (3.09 &#x000b1; 0.60 folds of change for 150&#x003bc;M DFX preconditioned cells and 5.06 &#x000b1; 1.86 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.16 folds of change for non-preconditioned cells) (<xref ref-type="fig" rid="pone.0178011.g002">Fig 2C</xref>) supporting the hypoxic inductive effect of DFX.</p></sec><sec id="sec017"><title>Deferoxamine preconditioning increases the expression and secretion of pro-angiogenic, neuroprotective and anti-inflammatory factors</title><p>It has been previously reported that high levels of HIF-1&#x003b1;, associated with hypoxic preconditioning, induce the expression and secretion of high levels of pro-angiogenic factors including VEGF&#x003b1; [<xref rid="pone.0178011.ref033" ref-type="bibr">33</xref>]. However, we wanted to evaluate if DFX preconditioning of AD-MSCs could also induce the expression and secretion of neuroprotective and anti-inflammatory factors relevant for the clinical management of DN.</p><p>As expected, we observed that preconditioning of MSCs with 150&#x003bc;M DFX or 400&#x003bc;M DFX induced a significant increase in the mRNA levels of the pro-angiogenic factors VEGF&#x003b1; and ANG-1, determined by RT-qPCR (<xref ref-type="fig" rid="pone.0178011.g003">Fig 3A</xref>) (for VEGF&#x003b1;: 12.66 &#x000b1; 4.42 folds of change for 150&#x003bc;M DFX preconditioned cells and 13.01 &#x000b1; 4.87 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.23 folds of change for non-preconditioned cells; for ANG-1: 4.24 &#x000b1; 2.35 folds of change for 150&#x003bc;M DFX preconditioned cells and 5.44 &#x000b1; 2.18 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.21 folds of change for non-preconditioned cells). Importantly, these preconditioning also induced the expression of the neuroprotective factors GDNF, NGF and NT3 (<xref ref-type="fig" rid="pone.0178011.g003">Fig 3B</xref>) (for GDNF: 5.08 &#x000b1; 3.37 folds of change for 150&#x003bc;M DFX preconditioned cells and 6.75 &#x000b1; 2.62 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.37 folds of change for non-preconditioned cells; for NGF: 2.56 &#x000b1; 0.46 folds of change for 150&#x003bc;M DFX preconditioned cells and 2.39 &#x000b1; 0.54 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.06 folds of change for non-preconditioned cells; for NT3: 5.26 &#x000b1; 1.33 folds of change for 150&#x003bc;M DFX preconditioned cells and 5.82 &#x000b1; 1.80 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.35 folds of change for non-preconditioned cells). We also observed a significant increase in the expression of the anti-inflammatory factors IL4 and IL5 (<xref ref-type="fig" rid="pone.0178011.g003">Fig 3C</xref>) (for IL4: 5.55 &#x000b1; 2.50 folds of change for 150&#x003bc;M DFX preconditioned cells and 7.43 &#x000b1; 2.89 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.20 folds of change for non-preconditioned cells; for IL5: 26.17 &#x000b1; 8.30 folds of change for 150&#x003bc;M DFX preconditioned cells and 26.85 &#x000b1; 8.53 folds of change for 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.30 folds of change for non-preconditioned cells). Increased expression of VEGF-&#x003b1;, ANG-1, GDNF, NGF, NT3, IL4 and IL5 after DFX preconditioning seems to be specific for the mentioned molecules, since this effect was not seen in other factors of the same families such as bFGF and PDGF (pro-angiogenic molecules), BDNF and CNTF (neuroprotective molecules), IL10 and TSG6 (anti-inflammatory molecules) (<xref ref-type="fig" rid="pone.0178011.g003">Fig 3A&#x02013;3C</xref>).</p><fig id="pone.0178011.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g003</object-id><label>Fig 3</label><caption><title>Deferoxamine preconditioning increases the expression levels of pro-angiogenic, neuroprotective and anti-inflammatory factors.</title><p>Total RNA was obtained from MSCs exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours and subjected to quantitative reverse transcriptase&#x02013;PCR analysis. (A) Quantification of the mRNA levels of the pro-angiogenic factors VEGF&#x003b1;, ANG1, bFGF and PDGF. (B) Quantification of the mRNA levels of the neuroprotective factors GDNF, NGF, NT3, BDNF and CNTF. (C) Quantification of the mRNA levels of the anti-inflammatory factors IL4, IL5, IL10 and TSG6. Data of each target gene was normalized against the mRNA levels of the housekeeping genes EEF1A1 and RPL13A of the same sample and presented as fold change of expression in preconditioned versus non-preconditioned cells. White bars represent non-preconditioned MSCs, gray bars represent MSCs preconditioned with 150&#x003bc;M DFX and black bars represent MSCs preconditioned with 400&#x003bc;M DFX. Data is shown as mean &#x000b1; SEM. N = 4 per experimental group (biological repeats). Experiments were repeated three times at technical level. * <italic>p&#x0003c; 0.05.</italic></p></caption><graphic xlink:href="pone.0178011.g003"/></fig><p>Next, we evaluated whether the increase in the mRNA levels observed after DFX preconditioning could also be correlated with an increase in the protein levels of these factors in the MSC secretome. For this, we chose a representative factor of each family and measured its protein level in the MSC secretomes by ELISA. In accordance with our RT-PCR data, we observed that preconditioning of MSCs by incubation with DFX (150&#x003bc;M or 400&#x003bc;M) induced a significant increase in the protein levels of the pro-angiogenic factor VEGF&#x003b1; and in the anti-inflammatory factor IL4 compared to the levels detected in the secretome of non-preconditioned MSCs (<xref ref-type="fig" rid="pone.0178011.g004">Fig 4A and 4C</xref>) (for VEGF&#x003b1;: 82.63 &#x000b1; 22.77 ng/ml in the secretome of 150&#x003bc;M DFX preconditioned cells and 100.8 &#x000b1; 19.35 ng/ml in the secretome of 400&#x003bc;M DFX preconditioned cells, compared to 8.75 &#x000b1; 2.13 ng/ml in the secretome of non-preconditioned cells; for IL4: 1.96 &#x000b1; 0.85 pg/ml in the secretome of 150&#x003bc;M DFX preconditioned cells and 4.33 &#x000b1; 0.82 pg/ml in the secretome of 400&#x003bc;M DFX preconditioned cells, compared to 0.42 &#x000b1; 0.18 pg/ml in the secretome of non-preconditioned cells). With regard to NGF and DFX, preconditioning induced an increase in the protein level of this neuroprotective factor; however, it did not reach statistical significance (<xref ref-type="fig" rid="pone.0178011.g004">Fig 4B</xref>) (409.5 &#x000b1; 135.4 pg/ml in the secretome of 150&#x003bc;M DFX preconditioned cells and 362.1 &#x000b1; 104.1 pg/ml in the secretome of 400&#x003bc;M DFX preconditioned cells, compared to 240.7 &#x000b1; 34.8 pg/ml in the secretome of non-preconditioned cells).</p><fig id="pone.0178011.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g004</object-id><label>Fig 4</label><caption><title>Deferoxamine preconditioning increases the secretion of pro-angiogenic, neuroprotective and anti-inflammatory factors.</title><p>The secretomes obtained from MSCs exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours were concentrated 10 times (v/v) using 3 kDa cutoff filters and the protein levels of selected factors were evaluated by ELISA. (A) Quantification of VEGF&#x003b1; in MSC secretomes. (B) Quantification of NGF in MSC secretomes. (C) Quantification of IL4 in MSC secretomes. Data is presented as mean &#x000b1; SEM. N = 4 per experimental group (biological repeats). Experiments were repeated three times at technical level. * <italic>p&#x0003c; 0.05</italic>.</p></caption><graphic xlink:href="pone.0178011.g004"/></fig></sec><sec id="sec018"><title>Deferoxamine preconditioning increases the antioxidant capacity of MSC secretomes</title><p>One of the regenerative mechanisms associated with the therapeutic effects of MSCs is the efficient handling of high levels of oxidative stress [<xref rid="pone.0178011.ref016" ref-type="bibr">16</xref>]. It has been proposed that some of the antioxidant molecules produced by MSCs could also be secreted [<xref rid="pone.0178011.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0178011.ref034" ref-type="bibr">34</xref>], reducing ROS levels in the surrounding microenvironment. Therefore, we evaluated whether DFX preconditioning of MSCs could increase the antioxidant capacity of the secretomes. The antioxidant system used in this study includes enzymes such as superoxide dismutase, catalase and glutathione peroxidase; macromolecules such as ferritin, and an array of small molecules including ascorbic acid, &#x003b1;-tocopherol, &#x003b2;-carotene, reduced glutathione, uric acid and bilirubin. Thus, the combined antioxidant activities of all the constituents of the MSC secretomes were assessed. We observed that DFX preconditioning significantly increased the antioxidant capacity of MSC secretomes in a concentration-dependent manner (<xref ref-type="fig" rid="pone.0178011.g005">Fig 5</xref>) (5.1 &#x000b1; 0.3 folds of change in the secretome of 150&#x003bc;M DFX preconditioned cells and 10.1 &#x000b1; 1 folds of change in the secretome of 400&#x003bc;M DFX preconditioned cells, compared to 1 &#x000b1; 0.07 folds of change in the secretome of non-preconditioned cells).</p><fig id="pone.0178011.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g005</object-id><label>Fig 5</label><caption><title>Deferoxamine preconditioning increases the antioxidant capacity of MSC secretomes.</title><p>The secretomes obtained from MSCs exposed to 150&#x003bc;M DFX, 400&#x003bc;M DFX or to the vehicle for 48 hours were concentrated 10 times (v/v) using 3 kDa cutoff filters. Total antioxidant capacity was quantified on the secretomes by colorimetric reactions. Data were expressed as fold change of total antioxidant activity in preconditioned versus non-preconditioned MSC secretomes. Data correspond to mean &#x000b1; SEM. N = 4 per experimental group (biological repeats). Experiments were repeated three times at technical level. * <italic>p&#x0003c; 0.05</italic>.</p></caption><graphic xlink:href="pone.0178011.g005"/></fig></sec><sec id="sec019"><title>Deferoxamine is not present in the final secretomes obtained from preconditioned MSCs</title><p>In order to use the MSC secretome as a therapeutic product, the preconditioning stimulus must be completely eliminated after the preconditioning process. Due to the small size of DFX, we aimed to eliminate this drug from the MSC secretomes subjecting them to two sequential washing and re-concentration steps. By HPLC, we observed that DFX was present in both (150&#x003bc;M and 400&#x003bc;M DFX) MSC secretomes before the washing steps, but its concentration was reduced to very low levels (below quantification limits) after the second washing step (<xref ref-type="fig" rid="pone.0178011.g006">Fig 6A and 6B</xref>).</p><fig id="pone.0178011.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g006</object-id><label>Fig 6</label><caption><title>Deferoxamine is not present in the final secretomes obtained from preconditioned MSCs.</title><p>The secretomes obtained from MSCs exposed to 150&#x003bc;M DFX or 400&#x003bc;M DFX for 48 hours were concentrated 10 times (v/v) using 3 kDa cutoff filters. The concentrates were washed twice with 15ml of PBS and re-concentrated again with the same filters. (A) Quantification by HPLC of DFX in the secretome of MSCs exposed to 400&#x003bc;M DFX before the washing steps and after the first and second washing steps. (B) Quantification by HPLC of DFX in the secretome of MSCs exposed to 150&#x003bc;M DFX before the washing steps and after the first and second washing steps. Quantitative data is presented as mean &#x000b1; SEM. N = 4 per experimental condition (biological repeats). Experiments were repeated three times at technical level. BQL: Below quantification limit.</p></caption><graphic xlink:href="pone.0178011.g006"/></fig></sec><sec id="sec020"><title>The secretomes of DFX preconditioned MSCs reduce glucose-induced DRG neuron death</title><p>Loss of DRG neurons has been described <italic>in vivo</italic> during DN [<xref rid="pone.0178011.ref035" ref-type="bibr">35</xref>] and <italic>in vitro</italic> after high-dose glucose-induced injury [<xref rid="pone.0178011.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0178011.ref037" ref-type="bibr">37</xref>]. Therefore, the <italic>in vitro</italic> stimulation of DRG neurons with diabetes-inducer conditions would allow for the screening of neuroprotective compounds with potential to prevent DN.</p><p>To evaluate the neuroprotective ability of the MSC secretomes, DRG neurons were pretreated with the secretomes of 150&#x003bc;M DFX preconditioned MSCs, the secretome of 400&#x003bc;M DFX preconditioned MSCs, the secretome of non-preconditioned MSCs or the vehicle. The dose for the secretomes was based on previous reports [<xref rid="pone.0178011.ref038" ref-type="bibr">38</xref>]. Four hours later, glucose level in culture media was raised from basal level (25mM glucose) to hyperglycemic level (45mM glucose). Twenty-four hours later, DRG neurons were fixed and TUNEL-stained.</p><p>As previously described, hyperglycemic insult induced a significant increase in the rate of apoptosis of DRG neurons (<xref ref-type="fig" rid="pone.0178011.g007">Fig 7A and 7B</xref>). (4.6 &#x000b1; 0.6% in the 45mM glucose DRG neurons compared to 1.8 &#x000b1; 0.2% in the 25mM glucose DRG neurons). Pre-incubation of DRG neurons with the secretome of non-preconditioned cells produced only a modest decrease in TUNEL positive cells, while the pre-incubation with the secretome of 150&#x003bc;M DFX and 400&#x003bc;M DFX preconditioned MSCs significantly decreased glucose-induced DRG neuron death (<xref ref-type="fig" rid="pone.0178011.g007">Fig 7A and 7B</xref>) (2.2 &#x000b1; 0.5% in DRG neurons pre-treated with secretome from 150&#x003bc;M DFX preconditioned MSCs; 1.6 &#x000b1; 0.3% in DRG neurons pre-treated with secretome from 400&#x003bc;M DFX preconditioned MSCs and 3.5 &#x000b1; 0.4% in DRG neurons pre-treated with secretome from non-preconditioned MSCs).</p><fig id="pone.0178011.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178011.g007</object-id><label>Fig 7</label><caption><title>The secretomes of DFX-preconditioned MSCs reduce glucose-induced DRG neuron death.</title><p>DRG neurons were pre-incubated with the secretomes of 150&#x003bc;M DFX-preconditioned MSCs, 400&#x003bc;M DFX-preconditioned MSCs or non-preconditioned MSCs for 4 hours. Hyperglycemic insult was then induced increasing glucose levels to 45mM. (A) Representative images of DRG neurons 24 hours after hyperglicemic insult. Green nuclei represent apoptotic TUNEL-stained cells (marked by arrows). Nuclei were counterstained with DAPI (blue). (B) Quantification of percentage of TUNEL-positive nuclei in each experimental condition. Quantitative data is presented as mean &#x000b1; SEM. N = 4 per experimental condition.</p></caption><graphic xlink:href="pone.0178011.g007"/></fig></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>Mesenchymal stem cells have emerged as a tool with great clinical potential. MSCs can be isolated from a wide range of tissues [<xref rid="pone.0178011.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0178011.ref040" ref-type="bibr">40</xref>], of which bone marrow is the traditional and most frequently used source. However, bone marrow aspiration is invasive and is accompanied with donor morbidity [<xref rid="pone.0178011.ref041" ref-type="bibr">41</xref>]. In contrast, adipose tissue is more accessible, can be obtained repeatedly under local anesthesia with a minimum of patient discomfort and has a higher yield of MSCs compared to that of bone marrow [<xref rid="pone.0178011.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0178011.ref043" ref-type="bibr">43</xref>]. Furthermore, AD-MSCs share many proprieties with bone marrow MSCs. Thus, adipose tissue is nowadays the preferred source of MSCs for regenerative therapy [<xref rid="pone.0178011.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0178011.ref043" ref-type="bibr">43</xref>]. Initially, it was postulated that the major mechanism associated with the therapeutic effects observed after the administration of MSCs in animal models of different diseases was related to the ability of these cells to migrate to damaged tissues, differentiate into the required cell type and replace dead cells [<xref rid="pone.0178011.ref044" ref-type="bibr">44</xref>]. However, it has been recently observed that the number of transplanted cells that reach and functionally integrate into damaged tissues is too low to account for their therapeutic effects [<xref rid="pone.0178011.ref045" ref-type="bibr">45</xref>]. Therefore, the generation of a pro-regenerative microenvironment, through the paracrine secretion of trophic factors, is now the most accepted therapeutic mechanism associated to MSCs. Thus, MSCs have been described as the &#x0201c;injury drugstore&#x0201d; of the body [<xref rid="pone.0178011.ref046" ref-type="bibr">46</xref>]. This phenomenon is also observed after local administration of MSCs in preclinical animal models of DN, in which it has not been possible to detect differentiation of MSCs into neurons, Schwann cells or endothelial cells despite an evident recovery of motor and sensory nerve conduction velocity, recovery of the normal structure of nerve fibers, and increased blood flow to damaged nerves [<xref rid="pone.0178011.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0178011.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0178011.ref047" ref-type="bibr">47</xref>]. These data suggest that different trophic factors secreted by MSCs are responsible for reducing the symptoms characteristic of DN.</p><p>The broad spectrum of molecules secreted by MSCs is known as the secretome. In humans, the MSCs secretome consists of over 100 biologically active molecules including different types of cytokines, chemokines, and growth factors [<xref rid="pone.0178011.ref048" ref-type="bibr">48</xref>]. In different pathologies such as acute myocardial infarction and brain or liver damage, it has been shown that the administration of the MSC secretome is able to reproduce, at least in part, the therapeutic effect observed after the administration of living cells [<xref rid="pone.0178011.ref049" ref-type="bibr">49</xref>, <xref rid="pone.0178011.ref050" ref-type="bibr">50</xref>] while at the same time reducing the therapy complexity and the cost. However, a major issue associated with the use of MSC secretome is that in most cases the concentration of cytokines and growth factors are too low for therapeutic use [<xref rid="pone.0178011.ref051" ref-type="bibr">51</xref>].</p><p>Recently, it has been reported that, due to the high plasticity of MSCs, it is possible to modify the MSC secretome baseline composition, by subjecting these cells to an <italic>in vitro</italic> preconditioning stimulus, producing a biological product with a defined combination and ratio of biomolecules specific for a determined pathology [<xref rid="pone.0178011.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0178011.ref025" ref-type="bibr">25</xref>].</p><p>In this context, many different strategies are being developed in order to boost the paracrine effect of MSCs, such as genetic engineering or pre-treatment with different physical or chemical factors. For example, it has been reported that preconditioning of MSCs with hypoxia (1%O<sub>2</sub>) stabilizes the HIF-1&#x003b1; protein and induces the secretion of high levels of pro-angiogenic factors [<xref rid="pone.0178011.ref052" ref-type="bibr">52</xref>], while the preconditioning of MSCs with LPS or IFN-&#x003b3; induces the secretion of molecules with anti-inflammatory activity [<xref rid="pone.0178011.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0178011.ref027" ref-type="bibr">27</xref>]. In this study, the iron chelator DFX was used as a preconditioning stimulus because it acts as a hypoxic mimetic agent, interfering with the degradation of HIF-1&#x003b1; [<xref rid="pone.0178011.ref053" ref-type="bibr">53</xref>]. We observed that the <italic>in vitro</italic> preconditioning of human AD-MSCs for 48 hours with two concentrations of DFX did not affect MSCs viability. As expected, these treatments induced the stabilization of HIF-1&#x003b1;, and led to the overexpression of genes related to pro-angiogenic responses including VEGF&#x003b1; and ANG-1. These results are in agreement with earlier studies indicating that DFX can induce VEGF&#x003b1; expression in various cell types, such as pancreatic beta cells [<xref rid="pone.0178011.ref054" ref-type="bibr">54</xref>], endothelial cells [<xref rid="pone.0178011.ref055" ref-type="bibr">55</xref>], and bone marrow stromal cells [<xref rid="pone.0178011.ref033" ref-type="bibr">33</xref>]. However, we also observed that the preconditioning of MSCs with DFX could also increase the expression of potent neuroprotective factors including NGF, GDNF and NT-3, and cytokines with anti-inflammatory activity such as IL4 and IL5. This enhancement in the production of therapeutic molecules after DFX preconditioning was specific for the mentioned factors, since this effect was not seen for other molecules of the same families <italic>e</italic>.<italic>g</italic>. bFGF, PDGF, BDNF, IL10, and TSG6. Additionally, this study demonstrated that the up-regulation of the mRNA levels of the mentioned factors correlates with an increased secretion of these protective molecules. This data suggests that modulation of culture conditions by incubation with DFX can be used to generate tailored MSCs, as well as to improve the MSC secretomes, making them suitable for different therapeutic applications.</p><p>Finally, we observed that the secretome obtained after the preconditioning of MSCs with DFX showed increased antioxidant capacity, enhancing its possible therapeutic use. These results corroborate previous reports indicating that MSCs are able to secrete high levels of molecules with antioxidant activities and also antioxidant enzymes including superoxide dismutase, catalase, and glutathione reductase [<xref rid="pone.0178011.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0178011.ref034" ref-type="bibr">34</xref>]. This study demonstrated that DFX preconditioning could also modulate the antioxidant properties of MSCs.</p><p>The pathogenesis of diabetic neuropathy is multifactorial, involving both metabolic and vascular components [<xref rid="pone.0178011.ref003" ref-type="bibr">3</xref>]. However, at the molecular level, the increase in ROS levels in mitochondria due to exacerbated glucose flux has been proposed as the central player in DN pathogenesis [<xref rid="pone.0178011.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0178011.ref007" ref-type="bibr">7</xref>]. It has been reported that high intracellular ROS levels can induce DN development acting on several levels. For example, neurons and Schwann cells are especially sensitive to the damage induced by ROS, due to their high density of mitochondria, which leads to cell apoptosis [<xref rid="pone.0178011.ref007" ref-type="bibr">7</xref>]. By secreting a broad range of neuroprotective factors (NGF, GDNF, NT-3, BDNF and CNTF), Schwann cells play a central role in neuron survival but also in the axonal regeneration of peripheral nerves after injury [<xref rid="pone.0178011.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0178011.ref057" ref-type="bibr">57</xref>]. Therefore, the early death of these cells in DN induces a significant reduction of the local levels of neuroprotective factors generating a vicious cycle that enhances nerve fiber degeneration and prevents their regeneration [<xref rid="pone.0178011.ref008" ref-type="bibr">8</xref>]. Of special importance are the neurotrophins NGF and NT-3. These trophic factors are clearly involved in growth, maintenance and survival of sympathetic and sensory neurons [<xref rid="pone.0178011.ref058" ref-type="bibr">58</xref>, <xref rid="pone.0178011.ref059" ref-type="bibr">59</xref>]. Additionally, increased ROS levels induce alterations in endothelial cells, generating loss of the vasodilation capacity of epineural blood vessels and reduction in pro-angiogenic factors production. This phenomenon leads to a reduction in the microcirculation of blood vessels that irrigate nerve fibers and the induction of ischemia and neuronal dysfunction [<xref rid="pone.0178011.ref060" ref-type="bibr">60</xref>, <xref rid="pone.0178011.ref061" ref-type="bibr">61</xref>].</p><p>Finally, increased oxidative stress also leads to the activation of the poly ADP-ribose polymerase (PARP) pathway, which is responsible for regulating pro-inflammatory cytokine expression. This creates a chronic inflammatory state that exerts direct toxic effect on neurons and Schwann cells. This process accelerates the demyelination and atrophy of the nerve fibers and contributes to the chronic pain characteristic of DN patients [<xref rid="pone.0178011.ref062" ref-type="bibr">62</xref>].</p><p>In diabetic rats, there is evidence of mitochondrial dysfunction and ROS accumulation in DRG neurons, followed by induction of apoptosis [<xref rid="pone.0178011.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0178011.ref063" ref-type="bibr">63</xref>]. Additionally, it has been reported that the <italic>in vitro</italic> incubation of DRG neurons with high glucose induces oxidative stress, caspase cleavage and the ultrastructural hallmarks of apoptosis [<xref rid="pone.0178011.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0178011.ref064" ref-type="bibr">64</xref>]. Thus, DRG neurons are a good model for the initial screening of potential drugs for the treatment of DN [<xref rid="pone.0178011.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0178011.ref064" ref-type="bibr">64</xref>].</p><p>Using this <italic>in vitro</italic> model we observed that incubation of DRG neurons with the secretomes of DFX preconditioned MSCs reduced their apoptotic rate after challenge with high glucose, suggesting a therapeutic potential of the studied secretomes.</p><p>High prevalence of DN has driven the effort to develop different types of experimental therapies guided to block the mechanisms involved in its progression. For example, oral or intravenous administrations of antioxidants, mainly -lipoic acid, in different animal models of DN produce an increase in nerve conduction velocity and a reduction in chronic pain [<xref rid="pone.0178011.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0178011.ref066" ref-type="bibr">66</xref>]. Additionally, the local administration of recombinant neuroprotective, pro-angiogenic, or anti-inflammatory factors was correlated with a decreased apoptosis of neurons and Schwann cells and with an increase in both motor and sensory nerve conduction velocity [<xref rid="pone.0178011.ref067" ref-type="bibr">67</xref>&#x02013;<xref rid="pone.0178011.ref072" ref-type="bibr">72</xref>].</p><p>However, while most of these therapies have shown positive results in diabetic animals, the transfer of these procedures to clinical studies has been very unsuccessful [<xref rid="pone.0178011.ref073" ref-type="bibr">73</xref>, <xref rid="pone.0178011.ref074" ref-type="bibr">74</xref>] and none of mentioned strategies are being routinely applied in clinical practice [<xref rid="pone.0178011.ref075" ref-type="bibr">75</xref>]. This seems to be mainly related to the fact that DN pathogenesis is multifactorial and involves many interrelated mechanisms. Therefore, a single molecule-based therapy is unlikely to be effective.</p><p>A therapeutic approach simultaneously targeting the angiogenic, neurodegenerative, inflammatory and oxidative processes, like the administration of the secretome of MSCs subjected to a preconditioning stimulus with DFX, may have great value in DN treatment. Furthermore, this treatment could be repeated over the time, since it does not generate an immunological rejection [<xref rid="pone.0178011.ref076" ref-type="bibr">76</xref>].</p><p>Compared to the use of living stem cells, this type of product has several advantages including: i) higher biosafety, since the administration of the MSC secretome has less bioethical considerations, and fewer risks of tumor formation than the administration of living cells; ii) immediate availability, since the MSC secretome can be lyophilized, favoring its storage, while living cells require extensive time for expansion; iii) greater reproducibility of the therapeutic effects, since biological variability of MSC secretomes can be minimized as it has a more defined composition (which can for instance be determined by a proteomic approach) while using MSCs may have more unpredictable effects; iv) easier handling, since biodrug administration is easier, safer and requires less complex medical facilities than those necessary for the administration of living cells: and v) lower production costs, since the MSC secretome can be produced in large quantities, reutilizing the cells. Therefore, the use of the MSC secretome as a therapy would reduce the high costs that are usually associated with the production of cell therapies for which the cells must be obtained and expanded for each patient.</p><p>Compared with other preconditioning stimuli like cobalt chloride, DFX has the advantage that it has been used in humans for more than three decades to treat iron overload diseases [<xref rid="pone.0178011.ref077" ref-type="bibr">77</xref>]. Therefore, it is believed that the administration of this agent to humans is safe. This study demonstrated that, even when used at high dose, DFX has no toxic effect on MSCs, which permits fine adjustment of the preconditioning by varying the concentration of DFX. However, one important feature for the clinical translation of this kind of biological therapy is that the preconditioning stimulus can be completely removed from the final product. In this sense, we have demonstrated that due to its small size, after two washing and re-concentration steps, DFX concentration could be reduced to undetectable levels.</p><p>Further evaluation is needed to demonstrate whether the local administration of the secretome of MSCs preconditioned with DFX could reverse the main functional and structural alterations characteristic of DN. Nevertheless, we believe that this strategy might also be useful for the treatment of others neurodegenerative disorders including amyotrophic lateral sclerosis, Huntinton&#x02019;s and Parkinson&#x02019;s disease and traumatic brain injury, in which the presence of neuroprotective, pro-angiogenic and anti-inflammatory factors are relevant [<xref rid="pone.0178011.ref078" ref-type="bibr">78</xref>]. We suggest that the administration of the secretome of MSCs preconditioned with DFX in animal models of these diseases could stimulate neural growth, decrease apoptosis, reduce levels of free radicals, enhance angiogenesis and regulate inflammation, promoting the functional recovery of the damaged organ.</p><p>Additionally, the preconditioning of MSCs with DFX could also be used prior to the administration of the cells to enhance their therapeutic effect. For example, it has been reported that one of the main factors that limits the therapeutic efficacy of MSCs is the poor survival of transplanted cells into the ischemic target tissue, which presents high levels of inflammatory factors and free radicals generated by oxidative stress [<xref rid="pone.0178011.ref079" ref-type="bibr">79</xref>]. Recent studies involving overexpression of anti-oxidant, anti-apoptotic, or anti-inflammatory genes in MSCs have shown improved survival after transplantation [<xref rid="pone.0178011.ref080" ref-type="bibr">80</xref>, <xref rid="pone.0178011.ref081" ref-type="bibr">81</xref>]. Therefore, the preconditioning of MSCs with DFX prior to their administration could also help to increase the tolerance of these cells to the hypoxic microenvironment, enhancing their survival in the damaged tissues. Furthermore, preconditioned MSCs may support the angiogenic process better than na&#x000ef;ve MSCs because they secrete more VEGF and enhance the proliferation and migration capacity of endothelial cells [<xref rid="pone.0178011.ref082" ref-type="bibr">82</xref>].</p><p>Finally, experiments using autologous MSCs from diabetic patients have suggested that these cells are less potent in their therapeutic potential, due to disease-induced cell dysfunction, limiting their clinical use [<xref rid="pone.0178011.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0178011.ref084" ref-type="bibr">84</xref>]. Still, the preconditioning we report here, with the overproduction of several trophic factors, could be a way to overcome these noxious defects.</p></sec><sec sec-type="conclusions" id="sec022"><title>Conclusions</title><p>Overexpression of survival molecules and growth factors appears to be a potent strategy to enable MSC therapeutics. This paper described a preconditioning strategy that led to an increase in the transcription and secretion of several potent pro-angiogenic, neuroprotective, and anti-inflammatory factors. The secretomes of preconditioned MSCs had neuroprotective effects when evaluated in an <italic>in vitro</italic> model of DN.</p><p>This upregulation of various classes of biologically important factors may be one of the greatest benefits of stem cell therapy compared to any single protein or gene therapy, enabling a concerted effect of multiple neuro-angiogenic and anti-inflammatory cytokines necessary for neurovascular recovery.</p></sec></body><back><ack><p>The authors thank Dr. Markus Uhrig, Dr. Anne Bliss and Dr. Carolina Rodriguez for proofreading the manuscript. This work was supported by the CIF-16 UDD grant and FONDECYT 1170712 grant awarded to Dr. Fernando Ezquer.</p></ack><ref-list><title>References</title><ref id="pone.0178011.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Guariguata</surname><given-names>L</given-names></name>, <name><surname>Whiting</surname><given-names>DR</given-names></name>, <name><surname>Hambleton</surname><given-names>I</given-names></name>, <name><surname>Beagley</surname><given-names>J</given-names></name>, <name><surname>Linnenkamp</surname><given-names>U</given-names></name>, <name><surname>Shaw</surname><given-names>JE</given-names></name>. <article-title>Global estimates of diabetes prevalence for 2013 and projections for 2035</article-title>. <source>Diabetes research and clinical practice</source>. <year>2014</year>;<volume>103</volume>(<issue>2</issue>):<fpage>137</fpage>&#x02013;<lpage>49</lpage>. Epub 2014/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.diabres.2013.11.002">10.1016/j.diabres.2013.11.002</ext-link></comment>
<?supplied-pmid 24630390?><pub-id pub-id-type="pmid">24630390</pub-id></mixed-citation></ref><ref id="pone.0178011.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Boulton</surname><given-names>AJ</given-names></name>, <name><surname>Vinik</surname><given-names>AI</given-names></name>, <name><surname>Arezzo</surname><given-names>JC</given-names></name>, <name><surname>Bril</surname><given-names>V</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>, <name><surname>Freeman</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Diabetic neuropathies: a statement by the American Diabetes Association</article-title>. <source>Diabetes care</source>. <year>2005</year>;<volume>28</volume>(<issue>4</issue>):<fpage>956</fpage>&#x02013;<lpage>62</lpage>. Epub 2005/03/29. <?supplied-pmid 15793206?><pub-id pub-id-type="pmid">15793206</pub-id></mixed-citation></ref><ref id="pone.0178011.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Bansal</surname><given-names>V</given-names></name>, <name><surname>Kalita</surname><given-names>J</given-names></name>, <name><surname>Misra</surname><given-names>UK</given-names></name>. <article-title>Diabetic neuropathy</article-title>. <source>Postgraduate medical journal</source>. <year>2006</year>;<volume>82</volume>(<issue>964</issue>):<fpage>95</fpage>&#x02013;<lpage>100</lpage>. Epub 2006/02/08. PubMed Central PMCID: PMC2596705. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/pgmj.2005.036137">10.1136/pgmj.2005.036137</ext-link></comment>
<?supplied-pmid 16461471?><pub-id pub-id-type="pmid">16461471</pub-id></mixed-citation></ref><ref id="pone.0178011.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Argoff</surname><given-names>CE</given-names></name>, <name><surname>Cole</surname><given-names>BE</given-names></name>, <name><surname>Fishbain</surname><given-names>DA</given-names></name>, <name><surname>Irving</surname><given-names>GA</given-names></name>. <article-title>Diabetic peripheral neuropathic pain: clinical and quality-of-life issues</article-title>. <source>Mayo Clinic proceedings</source>. <year>2006</year>;<volume>81</volume>(<issue>4 Suppl</issue>):<fpage>S3</fpage>&#x02013;<lpage>11</lpage>. Epub 2006/04/13. <?supplied-pmid 16608048?><pub-id pub-id-type="pmid">16608048</pub-id></mixed-citation></ref><ref id="pone.0178011.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Miyajima</surname><given-names>S</given-names></name>, <name><surname>Shirai</surname><given-names>A</given-names></name>, <name><surname>Yamamoto</surname><given-names>S</given-names></name>, <name><surname>Okada</surname><given-names>N</given-names></name>, <name><surname>Matsushita</surname><given-names>T</given-names></name>. <article-title>Risk factors for major limb amputations in diabetic foot gangrene patients</article-title>. <source>Diabetes research and clinical practice</source>. <year>2006</year>;<volume>71</volume>(<issue>3</issue>):<fpage>272</fpage>&#x02013;<lpage>9</lpage>. Epub 2005/09/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.diabres.2005.07.005">10.1016/j.diabres.2005.07.005</ext-link></comment>
<?supplied-pmid 16139385?><pub-id pub-id-type="pmid">16139385</pub-id></mixed-citation></ref><ref id="pone.0178011.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Figueroa-Romero</surname><given-names>C</given-names></name>, <name><surname>Sadidi</surname><given-names>M</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>Mechanisms of disease: the oxidative stress theory of diabetic neuropathy</article-title>. <source>Reviews in endocrine &#x00026; metabolic disorders</source>. <year>2008</year>;<volume>9</volume>(<issue>4</issue>):<fpage>301</fpage>&#x02013;<lpage>14</lpage>. Epub 2008/08/19. PubMed Central PMCID: PMC4239697.<pub-id pub-id-type="pmid">18709457</pub-id></mixed-citation></ref><ref id="pone.0178011.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Vincent</surname><given-names>AM</given-names></name>, <name><surname>Russell</surname><given-names>JW</given-names></name>, <name><surname>Low</surname><given-names>P</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>Oxidative stress in the pathogenesis of diabetic neuropathy</article-title>. <source>Endocrine reviews</source>. <year>2004</year>;<volume>25</volume>(<issue>4</issue>):<fpage>612</fpage>&#x02013;<lpage>28</lpage>. Epub 2004/08/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/er.2003-0019">10.1210/er.2003-0019</ext-link></comment>
<?supplied-pmid 15294884?><pub-id pub-id-type="pmid">15294884</pub-id></mixed-citation></ref><ref id="pone.0178011.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Tosaki</surname><given-names>T</given-names></name>, <name><surname>Kamiya</surname><given-names>H</given-names></name>, <name><surname>Yasuda</surname><given-names>Y</given-names></name>, <name><surname>Naruse</surname><given-names>K</given-names></name>, <name><surname>Kato</surname><given-names>K</given-names></name>, <name><surname>Kozakae</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons</article-title>. <source>Experimental neurology</source>. <year>2008</year>;<volume>213</volume>(<issue>2</issue>):<fpage>381</fpage>&#x02013;<lpage>7</lpage>. Epub 2008/08/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.expneurol.2008.06.017">10.1016/j.expneurol.2008.06.017</ext-link></comment>
<?supplied-pmid 18675804?><pub-id pub-id-type="pmid">18675804</pub-id></mixed-citation></ref><ref id="pone.0178011.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Leinninger</surname><given-names>GM</given-names></name>, <name><surname>Vincent</surname><given-names>AM</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>The role of growth factors in diabetic peripheral neuropathy</article-title>. <source>Journal of the peripheral nervous system: JPNS</source>. <year>2004</year>;<volume>9</volume>(<issue>1</issue>):<fpage>26</fpage>&#x02013;<lpage>53</lpage>. Epub 2004/02/12. <?supplied-pmid 14871451?><pub-id pub-id-type="pmid">14871451</pub-id></mixed-citation></ref><ref id="pone.0178011.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Argoff</surname><given-names>CE</given-names></name>, <name><surname>Backonja</surname><given-names>MM</given-names></name>, <name><surname>Belgrade</surname><given-names>MJ</given-names></name>, <name><surname>Bennett</surname><given-names>GJ</given-names></name>, <name><surname>Clark</surname><given-names>MR</given-names></name>, <name><surname>Cole</surname><given-names>BE</given-names></name>, <etal>et al</etal>
<article-title>Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain</article-title>. <source>Mayo Clinic proceedings</source>. <year>2006</year>;<volume>81</volume>(<issue>4 Suppl</issue>):<fpage>S12</fpage>&#x02013;<lpage>25</lpage>. Epub 2006/04/13. <?supplied-pmid 16608049?><pub-id pub-id-type="pmid">16608049</pub-id></mixed-citation></ref><ref id="pone.0178011.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Mizukami</surname><given-names>H</given-names></name>, <name><surname>Yagihashi</surname><given-names>S</given-names></name>. <article-title>Exploring a new therapy for diabetic polyneuropathy&#x02014;the application of stem cell transplantation</article-title>. <source>Frontiers in endocrinology</source>. <year>2014</year>;<volume>5</volume>:<fpage>45</fpage> Epub 2014/05/02. PubMed Central PMCID: PMC3988365. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2014.00045">10.3389/fendo.2014.00045</ext-link></comment>
<?supplied-pmid 24782826?><pub-id pub-id-type="pmid">24782826</pub-id></mixed-citation></ref><ref id="pone.0178011.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Prockop</surname><given-names>DJ</given-names></name>, <name><surname>Kota</surname><given-names>DJ</given-names></name>, <name><surname>Bazhanov</surname><given-names>N</given-names></name>, <name><surname>Reger</surname><given-names>RL</given-names></name>. <article-title>Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs)</article-title>. <source>Journal of cellular and molecular medicine</source>. <year>2010</year>;<volume>14</volume>(<issue>9</issue>):<fpage>2190</fpage>&#x02013;<lpage>9</lpage>. Epub 2010/08/19. PubMed Central PMCID: PMC3489272. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1582-4934.2010.01151.x">10.1111/j.1582-4934.2010.01151.x</ext-link></comment>
<?supplied-pmid 20716123?><pub-id pub-id-type="pmid">20716123</pub-id></mixed-citation></ref><ref id="pone.0178011.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Frausin</surname><given-names>S</given-names></name>, <name><surname>Viventi</surname><given-names>S</given-names></name>, <name><surname>Verga Falzacappa</surname><given-names>L</given-names></name>, <name><surname>Quattromani</surname><given-names>MJ</given-names></name>, <name><surname>Leanza</surname><given-names>G</given-names></name>, <name><surname>Tommasini</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research</article-title>. <source>Acta histochemica</source>. <year>2015</year>;<volume>117</volume>(<issue>4&#x02013;5</issue>):<fpage>329</fpage>&#x02013;<lpage>38</lpage>. Epub 2015/03/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.acthis.2015.02.005">10.1016/j.acthis.2015.02.005</ext-link></comment>
<?supplied-pmid 25747736?><pub-id pub-id-type="pmid">25747736</pub-id></mixed-citation></ref><ref id="pone.0178011.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Keilhoff</surname><given-names>G</given-names></name>, <name><surname>Stang</surname><given-names>F</given-names></name>, <name><surname>Goihl</surname><given-names>A</given-names></name>, <name><surname>Wolf</surname><given-names>G</given-names></name>, <name><surname>Fansa</surname><given-names>H</given-names></name>. <article-title>Transdifferentiated mesenchymal stem cells as alternative therapy in supporting nerve regeneration and myelination</article-title>. <source>Cellular and molecular neurobiology</source>. <year>2006</year>;<volume>26</volume>(<issue>7&#x02013;8</issue>):<fpage>1235</fpage>&#x02013;<lpage>52</lpage>. Epub 2006/06/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10571-006-9029-9">10.1007/s10571-006-9029-9</ext-link></comment>
<?supplied-pmid 16779672?><pub-id pub-id-type="pmid">16779672</pub-id></mixed-citation></ref><ref id="pone.0178011.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Caplan</surname><given-names>AI</given-names></name>, <name><surname>Dennis</surname><given-names>JE</given-names></name>. <article-title>Mesenchymal stem cells as trophic mediators</article-title>. <source>Journal of cellular biochemistry</source>. <year>2006</year>;<volume>98</volume>(<issue>5</issue>):<fpage>1076</fpage>&#x02013;<lpage>84</lpage>. Epub 2006/04/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jcb.20886">10.1002/jcb.20886</ext-link></comment>
<?supplied-pmid 16619257?><pub-id pub-id-type="pmid">16619257</pub-id></mixed-citation></ref><ref id="pone.0178011.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>WS</given-names></name>, <name><surname>Park</surname><given-names>BS</given-names></name>, <name><surname>Kim</surname><given-names>HK</given-names></name>, <name><surname>Park</surname><given-names>JS</given-names></name>, <name><surname>Kim</surname><given-names>KJ</given-names></name>, <name><surname>Choi</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress</article-title>. <source>Journal of dermatological science</source>. <year>2008</year>;<volume>49</volume>(<issue>2</issue>):<fpage>133</fpage>&#x02013;<lpage>42</lpage>. Epub 2007/09/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jdermsci.2007.08.004">10.1016/j.jdermsci.2007.08.004</ext-link></comment>
<?supplied-pmid 17870415?><pub-id pub-id-type="pmid">17870415</pub-id></mixed-citation></ref><ref id="pone.0178011.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Prockop</surname><given-names>DJ</given-names></name>, <name><surname>Oh</surname><given-names>JY</given-names></name>. <article-title>Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation</article-title>. <source>Molecular therapy: the journal of the American Society of Gene Therapy</source>. <year>2012</year>;<volume>20</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>20</lpage>. Epub 2011/10/20. PubMed Central PMCID: PMC3255583.</mixed-citation></ref><ref id="pone.0178011.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>BJ</given-names></name>, <name><surname>Jin</surname><given-names>HK</given-names></name>, <name><surname>Bae</surname><given-names>JS</given-names></name>. <article-title>Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy</article-title>. <source>Laboratory animal research</source>. <year>2011</year>;<volume>27</volume>(<issue>2</issue>):<fpage>171</fpage>&#x02013;<lpage>6</lpage>. Epub 2011/08/10. PubMed Central PMCID: PMC3146005. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5625/lar.2011.27.2.171">10.5625/lar.2011.27.2.171</ext-link></comment>
<?supplied-pmid 21826178?><pub-id pub-id-type="pmid">21826178</pub-id></mixed-citation></ref><ref id="pone.0178011.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Shibata</surname><given-names>T</given-names></name>, <name><surname>Naruse</surname><given-names>K</given-names></name>, <name><surname>Kamiya</surname><given-names>H</given-names></name>, <name><surname>Kozakae</surname><given-names>M</given-names></name>, <name><surname>Kondo</surname><given-names>M</given-names></name>, <name><surname>Yasuda</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats</article-title>. <source>Diabetes</source>. <year>2008</year>;<volume>57</volume>(<issue>11</issue>):<fpage>3099</fpage>&#x02013;<lpage>107</lpage>. Epub 2008/08/30. PubMed Central PMCID: PMC2570407. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db08-0031">10.2337/db08-0031</ext-link></comment>
<?supplied-pmid 18728233?><pub-id pub-id-type="pmid">18728233</pub-id></mixed-citation></ref><ref id="pone.0178011.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>JW</given-names></name>, <name><surname>Choi</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>MY</given-names></name>, <name><surname>Huh</surname><given-names>YH</given-names></name>, <name><surname>Yoon</surname><given-names>YS</given-names></name>. <article-title>Bone Marrow-Derived Mesenchymal Stem Cells Improve Diabetic Neuropathy by Direct Modulation of Both Angiogenesis and Myelination in Peripheral Nerves</article-title>. <source>Cell transplantation</source>. <year>2016</year>;<volume>25</volume>(<issue>2</issue>):<fpage>313</fpage>&#x02013;<lpage>26</lpage>. Epub 2015/05/16. PubMed Central PMCID: PMC4889908. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3727/096368915X688209">10.3727/096368915X688209</ext-link></comment>
<?supplied-pmid 25975801?><pub-id pub-id-type="pmid">25975801</pub-id></mixed-citation></ref><ref id="pone.0178011.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ezquer</surname><given-names>M</given-names></name>, <name><surname>Urzua</surname><given-names>CA</given-names></name>, <name><surname>Montecino</surname><given-names>S</given-names></name>, <name><surname>Leal</surname><given-names>K</given-names></name>, <name><surname>Conget</surname><given-names>P</given-names></name>, <name><surname>Ezquer</surname><given-names>F</given-names></name>. <article-title>Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice</article-title>. <source>Stem cell research &#x00026; therapy</source>. <year>2016</year>;<volume>7</volume>:<fpage>42</fpage>. Epub 2016/03/18. PubMed Central PMCID: PMC4793534.<pub-id pub-id-type="pmid">26983784</pub-id></mixed-citation></ref><ref id="pone.0178011.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>SP</given-names></name>, <name><surname>Wei</surname><given-names>Z</given-names></name>, <name><surname>Wei</surname><given-names>L</given-names></name>. <article-title>Preconditioning strategy in stem cell transplantation therapy</article-title>. <source>Translational stroke research</source>. <year>2013</year>;<volume>4</volume>(<issue>1</issue>):<fpage>76</fpage>&#x02013;<lpage>88</lpage>. Epub 2013/08/06. PubMed Central PMCID: PMC3728897. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12975-012-0251-0">10.1007/s12975-012-0251-0</ext-link></comment>
<?supplied-pmid 23914259?><pub-id pub-id-type="pmid">23914259</pub-id></mixed-citation></ref><ref id="pone.0178011.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Carriere</surname><given-names>A</given-names></name>, <name><surname>Ebrahimian</surname><given-names>TG</given-names></name>, <name><surname>Dehez</surname><given-names>S</given-names></name>, <name><surname>Auge</surname><given-names>N</given-names></name>, <name><surname>Joffre</surname><given-names>C</given-names></name>, <name><surname>Andre</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy</article-title>. <source>Arteriosclerosis, thrombosis, and vascular biology</source>. <year>2009</year>;<volume>29</volume>(<issue>7</issue>):<fpage>1093</fpage>&#x02013;<lpage>9</lpage>. Epub 2009/05/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/ATVBAHA.109.188318">10.1161/ATVBAHA.109.188318</ext-link></comment>
<?supplied-pmid 19423864?><pub-id pub-id-type="pmid">19423864</pub-id></mixed-citation></ref><ref id="pone.0178011.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Gao</surname><given-names>J</given-names></name>, <name><surname>Yuan</surname><given-names>Y</given-names></name>, <name><surname>Chang</surname><given-names>Q</given-names></name>, <name><surname>Liao</surname><given-names>Y</given-names></name>, <name><surname>Lu</surname><given-names>F</given-names></name>. <article-title>Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and bFGF</article-title>. <source>Cell biology international</source>. <year>2013</year>;<volume>37</volume>(<issue>6</issue>):<fpage>551</fpage>&#x02013;<lpage>60</lpage>. Epub 2013/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cbin.10097">10.1002/cbin.10097</ext-link></comment>
<?supplied-pmid 23505143?><pub-id pub-id-type="pmid">23505143</pub-id></mixed-citation></ref><ref id="pone.0178011.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Chacko</surname><given-names>SM</given-names></name>, <name><surname>Ahmed</surname><given-names>S</given-names></name>, <name><surname>Selvendiran</surname><given-names>K</given-names></name>, <name><surname>Kuppusamy</surname><given-names>ML</given-names></name>, <name><surname>Khan</surname><given-names>M</given-names></name>, <name><surname>Kuppusamy</surname><given-names>P</given-names></name>. <article-title>Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells</article-title>. <source>American journal of physiology Cell physiology</source>. <year>2010</year>;<volume>299</volume>(<issue>6</issue>):<fpage>C1562</fpage>&#x02013;<lpage>70</lpage>. Epub 2010/09/24. PubMed Central PMCID: PMC3006322. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpcell.00221.2010">10.1152/ajpcell.00221.2010</ext-link></comment>
<?supplied-pmid 20861473?><pub-id pub-id-type="pmid">20861473</pub-id></mixed-citation></ref><ref id="pone.0178011.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Krampera</surname><given-names>M</given-names></name>, <name><surname>Cosmi</surname><given-names>L</given-names></name>, <name><surname>Angeli</surname><given-names>R</given-names></name>, <name><surname>Pasini</surname><given-names>A</given-names></name>, <name><surname>Liotta</surname><given-names>F</given-names></name>, <name><surname>Andreini</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells</article-title>. <source>Stem cells</source>. <year>2006</year>;<volume>24</volume>(<issue>2</issue>):<fpage>386</fpage>&#x02013;<lpage>98</lpage>. Epub 2005/08/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/stemcells.2005-0008">10.1634/stemcells.2005-0008</ext-link></comment>
<?supplied-pmid 16123384?><pub-id pub-id-type="pmid">16123384</pub-id></mixed-citation></ref><ref id="pone.0178011.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Yao</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>F</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction</article-title>. <source>Journal of biomedical science</source>. <year>2009</year>;<volume>16</volume>:<fpage>74</fpage> Epub 2009/08/21. PubMed Central PMCID: PMC2739513. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1423-0127-16-74">10.1186/1423-0127-16-74</ext-link></comment>
<?supplied-pmid 19691857?><pub-id pub-id-type="pmid">19691857</pub-id></mixed-citation></ref><ref id="pone.0178011.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Dominici</surname><given-names>M</given-names></name>, <name><surname>Le Blanc</surname><given-names>K</given-names></name>, <name><surname>Mueller</surname><given-names>I</given-names></name>, <name><surname>Slaper-Cortenbach</surname><given-names>I</given-names></name>, <name><surname>Marini</surname><given-names>F</given-names></name>, <name><surname>Krause</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement</article-title>. <source>Cytotherapy</source>. <year>2006</year>;<volume>8</volume>(<issue>4</issue>):<fpage>315</fpage>&#x02013;<lpage>7</lpage>. Epub 2006/08/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14653240600855905">10.1080/14653240600855905</ext-link></comment>
<?supplied-pmid 16923606?><pub-id pub-id-type="pmid">16923606</pub-id></mixed-citation></ref><ref id="pone.0178011.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>De Francia</surname><given-names>S</given-names></name>, <name><surname>Massano</surname><given-names>D</given-names></name>, <name><surname>Piccione</surname><given-names>FM</given-names></name>, <name><surname>Pirro</surname><given-names>E</given-names></name>, <name><surname>Racca</surname><given-names>S</given-names></name>, <name><surname>Di Carlo</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients</article-title>. <source>J Chromatogr B</source>. <year>2012</year>;<volume>893</volume>:<fpage>127</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="pone.0178011.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Acosta</surname><given-names>C</given-names></name>, <name><surname>McMullan</surname><given-names>S</given-names></name>, <name><surname>Djouhri</surname><given-names>L</given-names></name>, <name><surname>Gao</surname><given-names>L</given-names></name>, <name><surname>Watkins</surname><given-names>R</given-names></name>, <name><surname>Berry</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>HCN1 and HCN2 in Rat DRG neurons: levels in nociceptors and non-nociceptors, NT3-dependence and influence of CFA-induced skin inflammation on HCN2 and NT3 expression</article-title>. <source>PloS one</source>. <year>2012</year>;<volume>7</volume>(<issue>12</issue>):<fpage>e50442</fpage> Epub 2012/12/14. PubMed Central PMCID: PMC3517619. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0050442">10.1371/journal.pone.0050442</ext-link></comment>
<?supplied-pmid 23236374?><pub-id pub-id-type="pmid">23236374</pub-id></mixed-citation></ref><ref id="pone.0178011.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Nouri</surname><given-names>F</given-names></name>, <name><surname>Salehinejad</surname><given-names>P</given-names></name>, <name><surname>Nematollahi-Mahani</surname><given-names>SN</given-names></name>, <name><surname>Kamarul</surname><given-names>T</given-names></name>, <name><surname>Zarrindast</surname><given-names>MR</given-names></name>, <name><surname>Sharifi</surname><given-names>AM</given-names></name>. <article-title>Deferoxamine Preconditioning of Neural-Like Cells Derived from Human Wharton's Jelly Mesenchymal Stem Cells as a Strategy to Promote Their Tolerance and Therapeutic Potential: An In Vitro Study</article-title>. <source>Cellular and molecular neurobiology</source>. <year>2016</year>;<volume>36</volume>(<issue>5</issue>):<fpage>689</fpage>&#x02013;<lpage>700</lpage>. Epub 2015/08/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10571-015-0249-8">10.1007/s10571-015-0249-8</ext-link></comment>
<?supplied-pmid 26242172?><pub-id pub-id-type="pmid">26242172</pub-id></mixed-citation></ref><ref id="pone.0178011.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>K</given-names></name>, <name><surname>Jung</surname><given-names>KH</given-names></name>, <name><surname>Kim</surname><given-names>SJ</given-names></name>, <name><surname>Lee</surname><given-names>ST</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Park</surname><given-names>HK</given-names></name>, <etal>et al</etal>
<article-title>Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain</article-title>. <source>Brain research</source>. <year>2008</year>;<volume>1207</volume>:<fpage>182</fpage>&#x02013;<lpage>92</lpage>. Epub 2008/03/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.brainres.2008.02.043">10.1016/j.brainres.2008.02.043</ext-link></comment>
<?supplied-pmid 18371939?><pub-id pub-id-type="pmid">18371939</pub-id></mixed-citation></ref><ref id="pone.0178011.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Potier</surname><given-names>E</given-names></name>, <name><surname>Ferreira</surname><given-names>E</given-names></name>, <name><surname>Dennler</surname><given-names>S</given-names></name>, <name><surname>Mauviel</surname><given-names>A</given-names></name>, <name><surname>Oudina</surname><given-names>K</given-names></name>, <name><surname>Logeart-Avramoglou</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Desferrioxamine-driven upregulation of angiogenic factor expression by human bone marrow stromal cells</article-title>. <source>Journal of tissue engineering and regenerative medicine</source>. <year>2008</year>;<volume>2</volume>(<issue>5</issue>):<fpage>272</fpage>&#x02013;<lpage>8</lpage>. Epub 2008/05/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/term.92">10.1002/term.92</ext-link></comment>
<?supplied-pmid 18512268?><pub-id pub-id-type="pmid">18512268</pub-id></mixed-citation></ref><ref id="pone.0178011.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Waszak</surname><given-names>P</given-names></name>, <name><surname>Alphonse</surname><given-names>R</given-names></name>, <name><surname>Vadivel</surname><given-names>A</given-names></name>, <name><surname>Ionescu</surname><given-names>L</given-names></name>, <name><surname>Eaton</surname><given-names>F</given-names></name>, <name><surname>Thebaud</surname><given-names>B</given-names></name>. <article-title>Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats</article-title>. <source>Stem cells and development</source>. <year>2012</year>;<volume>21</volume>(<issue>15</issue>):<fpage>2789</fpage>&#x02013;<lpage>97</lpage>. Epub 2012/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/scd.2010.0566">10.1089/scd.2010.0566</ext-link></comment>
<?supplied-pmid 22533467?><pub-id pub-id-type="pmid">22533467</pub-id></mixed-citation></ref><ref id="pone.0178011.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Shimoshige</surname><given-names>Y</given-names></name>, <name><surname>Minoura</surname><given-names>K</given-names></name>, <name><surname>Matsuoka</surname><given-names>N</given-names></name>, <name><surname>Takakura</surname><given-names>S</given-names></name>, <name><surname>Mutoh</surname><given-names>S</given-names></name>, <name><surname>Kamijo</surname><given-names>M</given-names></name>. <article-title>Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats</article-title>. <source>Brain research</source>. <year>2009</year>;<volume>1247</volume>:<fpage>182</fpage>&#x02013;<lpage>7</lpage>. Epub 2008/11/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.brainres.2008.10.018">10.1016/j.brainres.2008.10.018</ext-link></comment>
<?supplied-pmid 18992730?><pub-id pub-id-type="pmid">18992730</pub-id></mixed-citation></ref><ref id="pone.0178011.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Leinninger</surname><given-names>GM</given-names></name>, <name><surname>Backus</surname><given-names>C</given-names></name>, <name><surname>Sastry</surname><given-names>AM</given-names></name>, <name><surname>Yi</surname><given-names>YB</given-names></name>, <name><surname>Wang</surname><given-names>CW</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1</article-title>. <source>Neurobiology of disease</source>. <year>2006</year>;<volume>23</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>22</lpage>. Epub 2006/05/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbd.2006.01.017">10.1016/j.nbd.2006.01.017</ext-link></comment>
<?supplied-pmid 16684605?><pub-id pub-id-type="pmid">16684605</pub-id></mixed-citation></ref><ref id="pone.0178011.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Vincent</surname><given-names>AM</given-names></name>, <name><surname>Stevens</surname><given-names>MJ</given-names></name>, <name><surname>Backus</surname><given-names>C</given-names></name>, <name><surname>McLean</surname><given-names>LL</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury</article-title>. <source>Antioxidants &#x00026; redox signaling</source>. <year>2005</year>;<volume>7</volume>(<issue>11&#x02013;12</issue>):<fpage>1494</fpage>&#x02013;<lpage>506</lpage>. Epub 2005/12/17.<pub-id pub-id-type="pmid">16356113</pub-id></mixed-citation></ref><ref id="pone.0178011.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Hao</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Du</surname><given-names>Y</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Mesenchymal Stem Cell Conditioned Medium Promotes Proliferation and Migration of Alveolar Epithelial Cells under Septic Conditions In Vitro via the JNK-P38 Signaling Pathway</article-title>. <source>Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology</source>. <year>2015</year>;<volume>37</volume>(<issue>5</issue>):<fpage>1830</fpage>&#x02013;<lpage>46</lpage>. Epub 2015/11/20.</mixed-citation></ref><ref id="pone.0178011.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>da Silva Meirelles</surname><given-names>L</given-names></name>, <name><surname>Chagastelles</surname><given-names>PC</given-names></name>, <name><surname>Nardi</surname><given-names>NB</given-names></name>. <article-title>Mesenchymal stem cells reside in virtually all post-natal organs and tissues</article-title>. <source>Journal of cell science</source>. <year>2006</year>;<volume>119</volume>(<issue>Pt 11</issue>):<fpage>2204</fpage>&#x02013;<lpage>13</lpage>. Epub 2006/05/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1242/jcs.02932">10.1242/jcs.02932</ext-link></comment>
<?supplied-pmid 16684817?><pub-id pub-id-type="pmid">16684817</pub-id></mixed-citation></ref><ref id="pone.0178011.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Hoogduijn</surname><given-names>MJ</given-names></name>, <name><surname>Crop</surname><given-names>MJ</given-names></name>, <name><surname>Peeters</surname><given-names>AM</given-names></name>, <name><surname>Van Osch</surname><given-names>GJ</given-names></name>, <name><surname>Balk</surname><given-names>AH</given-names></name>, <name><surname>Ijzermans</surname><given-names>JN</given-names></name>, <etal>et al</etal>
<article-title>Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities</article-title>. <source>Stem cells and development</source>. <year>2007</year>;<volume>16</volume>(<issue>4</issue>):<fpage>597</fpage>&#x02013;<lpage>604</lpage>. Epub 2007/09/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/scd.2006.0110">10.1089/scd.2006.0110</ext-link></comment>
<?supplied-pmid 17784833?><pub-id pub-id-type="pmid">17784833</pub-id></mixed-citation></ref><ref id="pone.0178011.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Nishimori</surname><given-names>M</given-names></name>, <name><surname>Yamada</surname><given-names>Y</given-names></name>, <name><surname>Hoshi</surname><given-names>K</given-names></name>, <name><surname>Akiyama</surname><given-names>Y</given-names></name>, <name><surname>Hoshi</surname><given-names>Y</given-names></name>, <name><surname>Morishima</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Health-related quality of life of unrelated bone marrow donors in Japan</article-title>. <source>Blood</source>. <year>2002</year>;<volume>99</volume>(<issue>6</issue>):<fpage>1995</fpage>&#x02013;<lpage>2001</lpage>. Epub 2002/03/06. <?supplied-pmid 11877271?><pub-id pub-id-type="pmid">11877271</pub-id></mixed-citation></ref><ref id="pone.0178011.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HC</given-names></name>, <name><surname>An</surname><given-names>SG</given-names></name>, <name><surname>Lee</surname><given-names>HW</given-names></name>, <name><surname>Park</surname><given-names>JS</given-names></name>, <name><surname>Cha</surname><given-names>KS</given-names></name>, <name><surname>Hong</surname><given-names>TJ</given-names></name>, <etal>et al</etal>
<article-title>Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study</article-title>. <source>Circulation journal: official journal of the Japanese Circulation Society</source>. <year>2012</year>;<volume>76</volume>(<issue>7</issue>):<fpage>1750</fpage>&#x02013;<lpage>60</lpage>. Epub 2012/04/14.<pub-id pub-id-type="pmid">22498564</pub-id></mixed-citation></ref><ref id="pone.0178011.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Garcia-Olmo</surname><given-names>D</given-names></name>, <name><surname>Herreros</surname><given-names>D</given-names></name>, <name><surname>Pascual</surname><given-names>I</given-names></name>, <name><surname>Pascual</surname><given-names>JA</given-names></name>, <name><surname>Del-Valle</surname><given-names>E</given-names></name>, <name><surname>Zorrilla</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial</article-title>. <source>Diseases of the colon and rectum</source>. <year>2009</year>;<volume>52</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>86</lpage>. Epub 2009/03/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/DCR.0b013e3181973487">10.1007/DCR.0b013e3181973487</ext-link></comment>
<?supplied-pmid 19273960?><pub-id pub-id-type="pmid">19273960</pub-id></mixed-citation></ref><ref id="pone.0178011.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>L</given-names></name>, <name><surname>Tuan</surname><given-names>RS</given-names></name>. <article-title>Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow</article-title>. <source>FASEB journal: official publication of the Federation of American Societies for Experimental Biology</source>. <year>2004</year>;<volume>18</volume>(<issue>9</issue>):<fpage>980</fpage>&#x02013;<lpage>2</lpage>. Epub 2004/04/16.<pub-id pub-id-type="pmid">15084518</pub-id></mixed-citation></ref><ref id="pone.0178011.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Phinney</surname><given-names>DG</given-names></name>, <name><surname>Prockop</surname><given-names>DJ</given-names></name>. <article-title>Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair&#x02014;current views</article-title>. <source>Stem cells</source>. <year>2007</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2896</fpage>&#x02013;<lpage>902</lpage>. Epub 2007/09/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/stemcells.2007-0637">10.1634/stemcells.2007-0637</ext-link></comment>
<?supplied-pmid 17901396?><pub-id pub-id-type="pmid">17901396</pub-id></mixed-citation></ref><ref id="pone.0178011.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Caplan</surname><given-names>AI</given-names></name>, <name><surname>Correa</surname><given-names>D</given-names></name>. <article-title>The MSC: an injury drugstore</article-title>. <source>Cell stem cell</source>. <year>2011</year>;<volume>9</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>5</lpage>. Epub 2011/07/06. PubMed Central PMCID: PMC3144500. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.stem.2011.06.008">10.1016/j.stem.2011.06.008</ext-link></comment>
<?supplied-pmid 21726829?><pub-id pub-id-type="pmid">21726829</pub-id></mixed-citation></ref><ref id="pone.0178011.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Naruse</surname><given-names>K</given-names></name>, <name><surname>Sato</surname><given-names>J</given-names></name>, <name><surname>Funakubo</surname><given-names>M</given-names></name>, <name><surname>Hata</surname><given-names>M</given-names></name>, <name><surname>Nakamura</surname><given-names>N</given-names></name>, <name><surname>Kobayashi</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy</article-title>. <source>PloS one</source>. <year>2011</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e27458</fpage> Epub 2011/11/30. PubMed Central PMCID: PMC3220696. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0027458">10.1371/journal.pone.0027458</ext-link></comment>
<?supplied-pmid 22125614?><pub-id pub-id-type="pmid">22125614</pub-id></mixed-citation></ref><ref id="pone.0178011.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Salgado</surname><given-names>AJ</given-names></name>, <name><surname>Reis</surname><given-names>RL</given-names></name>, <name><surname>Sousa</surname><given-names>NJ</given-names></name>, <name><surname>Gimble</surname><given-names>JM</given-names></name>. <article-title>Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine</article-title>. <source>Current stem cell research &#x00026; therapy</source>. <year>2010</year>;<volume>5</volume>(<issue>2</issue>):<fpage>103</fpage>&#x02013;<lpage>10</lpage>. Epub 2009/11/28.<pub-id pub-id-type="pmid">19941460</pub-id></mixed-citation></ref><ref id="pone.0178011.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SC</given-names></name>, <name><surname>Kim</surname><given-names>JO</given-names></name>, <name><surname>Kim</surname><given-names>SJ</given-names></name>. <article-title>Secretome from human adipose-derived stem cells protects mouse liver from hepatic ischemia-reperfusion injury</article-title>. <source>Surgery</source>. <year>2015</year>;<volume>157</volume>(<issue>5</issue>):<fpage>934</fpage>&#x02013;<lpage>43</lpage>. Epub 2015/02/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.surg.2014.12.016">10.1016/j.surg.2014.12.016</ext-link></comment>
<?supplied-pmid 25704431?><pub-id pub-id-type="pmid">25704431</pub-id></mixed-citation></ref><ref id="pone.0178011.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>X</given-names></name>, <name><surname>Du</surname><given-names>Z</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Feng</surname><given-names>D</given-names></name>, <name><surname>Wei</surname><given-names>G</given-names></name>, <name><surname>He</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats</article-title>. <source>Stem cells</source>. <year>2009</year>;<volume>27</volume>(<issue>2</issue>):<fpage>478</fpage>&#x02013;<lpage>88</lpage>. Epub 2008/11/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1634/stemcells.2008-0333">10.1634/stemcells.2008-0333</ext-link></comment>
<?supplied-pmid 19023032?><pub-id pub-id-type="pmid">19023032</pub-id></mixed-citation></ref><ref id="pone.0178011.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Angoulvant</surname><given-names>D</given-names></name>, <name><surname>Ivanes</surname><given-names>F</given-names></name>, <name><surname>Ferrera</surname><given-names>R</given-names></name>, <name><surname>Matthews</surname><given-names>PG</given-names></name>, <name><surname>Nataf</surname><given-names>S</given-names></name>, <name><surname>Ovize</surname><given-names>M</given-names></name>. <article-title>Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury</article-title>. <source>The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation</source>. <year>2011</year>;<volume>30</volume>(<issue>1</issue>):<fpage>95</fpage>&#x02013;<lpage>102</lpage>. Epub 2010/10/30.</mixed-citation></ref><ref id="pone.0178011.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Stubbs</surname><given-names>SL</given-names></name>, <name><surname>Hsiao</surname><given-names>ST</given-names></name>, <name><surname>Peshavariya</surname><given-names>HM</given-names></name>, <name><surname>Lim</surname><given-names>SY</given-names></name>, <name><surname>Dusting</surname><given-names>GJ</given-names></name>, <name><surname>Dilley</surname><given-names>RJ</given-names></name>. <article-title>Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro</article-title>. <source>Stem cells and development</source>. <year>2012</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1887</fpage>&#x02013;<lpage>96</lpage>. Epub 2011/12/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/scd.2011.0289">10.1089/scd.2011.0289</ext-link></comment>
<?supplied-pmid 22165914?><pub-id pub-id-type="pmid">22165914</pub-id></mixed-citation></ref><ref id="pone.0178011.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Jaakkola</surname><given-names>P</given-names></name>, <name><surname>Mole</surname><given-names>DR</given-names></name>, <name><surname>Tian</surname><given-names>YM</given-names></name>, <name><surname>Wilson</surname><given-names>MI</given-names></name>, <name><surname>Gielbert</surname><given-names>J</given-names></name>, <name><surname>Gaskell</surname><given-names>SJ</given-names></name>, <etal>et al</etal>
<article-title>Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation</article-title>. <source>Science</source>. <year>2001</year>;<volume>292</volume>(<issue>5516</issue>):<fpage>468</fpage>&#x02013;<lpage>72</lpage>. Epub 2001/04/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1059796">10.1126/science.1059796</ext-link></comment>
<?supplied-pmid 11292861?><pub-id pub-id-type="pmid">11292861</pub-id></mixed-citation></ref><ref id="pone.0178011.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Langlois</surname><given-names>A</given-names></name>, <name><surname>Bietiger</surname><given-names>W</given-names></name>, <name><surname>Mandes</surname><given-names>K</given-names></name>, <name><surname>Maillard</surname><given-names>E</given-names></name>, <name><surname>Belcourt</surname><given-names>A</given-names></name>, <name><surname>Pinget</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Overexpression of vascular endothelial growth factor in vitro using deferoxamine: a new drug to increase islet vascularization during transplantation</article-title>. <source>Transplantation proceedings</source>. <year>2008</year>;<volume>40</volume>(<issue>2</issue>):<fpage>473</fpage>&#x02013;<lpage>6</lpage>. Epub 2008/04/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.transproceed.2008.01.003">10.1016/j.transproceed.2008.01.003</ext-link></comment>
<?supplied-pmid 18374106?><pub-id pub-id-type="pmid">18374106</pub-id></mixed-citation></ref><ref id="pone.0178011.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Yamakawa</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>LX</given-names></name>, <name><surname>Date</surname><given-names>T</given-names></name>, <name><surname>Belanger</surname><given-names>AJ</given-names></name>, <name><surname>Vincent</surname><given-names>KA</given-names></name>, <name><surname>Akita</surname><given-names>GY</given-names></name>, <etal>et al</etal>
<article-title>Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors</article-title>. <source>Circulation research</source>. <year>2003</year>;<volume>93</volume>(<issue>7</issue>):<fpage>664</fpage>&#x02013;<lpage>73</lpage>. Epub 2003/09/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.RES.0000093984.48643.D7">10.1161/01.RES.0000093984.48643.D7</ext-link></comment>
<?supplied-pmid 12958144?><pub-id pub-id-type="pmid">12958144</pub-id></mixed-citation></ref><ref id="pone.0178011.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Schmeichel</surname><given-names>AM</given-names></name>, <name><surname>Schmelzer</surname><given-names>JD</given-names></name>, <name><surname>Low</surname><given-names>PA</given-names></name>. <article-title>Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy</article-title>. <source>Diabetes</source>. <year>2003</year>;<volume>52</volume>(<issue>1</issue>):<fpage>165</fpage>&#x02013;<lpage>71</lpage>. Epub 2002/12/28. <?supplied-pmid 12502508?><pub-id pub-id-type="pmid">12502508</pub-id></mixed-citation></ref><ref id="pone.0178011.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Kalichman</surname><given-names>MW</given-names></name>, <name><surname>Powell</surname><given-names>HC</given-names></name>, <name><surname>Mizisin</surname><given-names>AP</given-names></name>. <article-title>Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy</article-title>. <source>Acta neuropathologica</source>. <year>1998</year>;<volume>95</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>56</lpage>. Epub 1998/02/07. <?supplied-pmid 9452821?><pub-id pub-id-type="pmid">9452821</pub-id></mixed-citation></ref><ref id="pone.0178011.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Fiore</surname><given-names>M</given-names></name>, <name><surname>Chaldakov</surname><given-names>GN</given-names></name>, <name><surname>Aloe</surname><given-names>L</given-names></name>. <article-title>Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems</article-title>. <source>Reviews in the neurosciences</source>. <year>2009</year>;<volume>20</volume>(<issue>2</issue>):<fpage>133</fpage>&#x02013;<lpage>45</lpage>. Epub 2009/09/25. <?supplied-pmid 19774790?><pub-id pub-id-type="pmid">19774790</pub-id></mixed-citation></ref><ref id="pone.0178011.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Apfel</surname><given-names>SC</given-names></name>. <article-title>Neurotrophic factors in the therapy of diabetic neuropathy</article-title>. <source>The American journal of medicine</source>. <year>1999</year>;<volume>107</volume>(<issue>2B</issue>):<fpage>34S</fpage>&#x02013;<lpage>42S</lpage>. Epub 1999/09/14. <?supplied-pmid 10484043?><pub-id pub-id-type="pmid">10484043</pub-id></mixed-citation></ref><ref id="pone.0178011.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Coppey</surname><given-names>LJ</given-names></name>, <name><surname>Gellett</surname><given-names>JS</given-names></name>, <name><surname>Davidson</surname><given-names>EP</given-names></name>, <name><surname>Dunlap</surname><given-names>JA</given-names></name>, <name><surname>Lund</surname><given-names>DD</given-names></name>, <name><surname>Yorek</surname><given-names>MA</given-names></name>. <article-title>Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve</article-title>. <source>Diabetes</source>. <year>2001</year>;<volume>50</volume>(<issue>8</issue>):<fpage>1927</fpage>&#x02013;<lpage>37</lpage>. Epub 2001/07/27. <?supplied-pmid 11473057?><pub-id pub-id-type="pmid">11473057</pub-id></mixed-citation></ref><ref id="pone.0178011.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Coppey</surname><given-names>LJ</given-names></name>, <name><surname>Gellett</surname><given-names>JS</given-names></name>, <name><surname>Davidson</surname><given-names>EP</given-names></name>, <name><surname>Yorek</surname><given-names>MA</given-names></name>. <article-title>Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation</article-title>. <source>Free radical research</source>. <year>2003</year>;<volume>37</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>40</lpage>. Epub 2003/03/26. <?supplied-pmid 12653215?><pub-id pub-id-type="pmid">12653215</pub-id></mixed-citation></ref><ref id="pone.0178011.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Vincent</surname><given-names>AM</given-names></name>, <name><surname>Callaghan</surname><given-names>BC</given-names></name>, <name><surname>Smith</surname><given-names>AL</given-names></name>, <name><surname>Feldman</surname><given-names>EL</given-names></name>. <article-title>Diabetic neuropathy: cellular mechanisms as therapeutic targets</article-title>. <source>Nature reviews Neurology</source>. <year>2011</year>;<volume>7</volume>(<issue>10</issue>):<fpage>573</fpage>&#x02013;<lpage>83</lpage>. Epub 2011/09/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneurol.2011.137">10.1038/nrneurol.2011.137</ext-link></comment>
<?supplied-pmid 21912405?><pub-id pub-id-type="pmid">21912405</pub-id></mixed-citation></ref><ref id="pone.0178011.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Kishi</surname><given-names>M</given-names></name>, <name><surname>Tanabe</surname><given-names>J</given-names></name>, <name><surname>Schmelzer</surname><given-names>JD</given-names></name>, <name><surname>Low</surname><given-names>PA</given-names></name>. <article-title>Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy</article-title>. <source>Diabetes</source>. <year>2002</year>;<volume>51</volume>(<issue>3</issue>):<fpage>819</fpage>&#x02013;<lpage>24</lpage>. Epub 2002/03/02. <?supplied-pmid 11872686?><pub-id pub-id-type="pmid">11872686</pub-id></mixed-citation></ref><ref id="pone.0178011.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Liang</surname><given-names>XC</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>Q</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Anti-oxidative and anti-inflammatory effects of cinnamaldehyde on protecting high glucose-induced damage in cultured dorsal root ganglion neurons of rats</article-title>. <source>Chinese journal of integrative medicine</source>. <year>2016</year>;<volume>22</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>27</lpage>. Epub 2015/11/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11655-015-2103-8">10.1007/s11655-015-2103-8</ext-link></comment>
<?supplied-pmid 26577110?><pub-id pub-id-type="pmid">26577110</pub-id></mixed-citation></ref><ref id="pone.0178011.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Stevens</surname><given-names>MJ</given-names></name>, <name><surname>Obrosova</surname><given-names>I</given-names></name>, <name><surname>Cao</surname><given-names>X</given-names></name>, <name><surname>Van Huysen</surname><given-names>C</given-names></name>, <name><surname>Greene</surname><given-names>DA</given-names></name>. <article-title>Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy</article-title>. <source>Diabetes</source>. <year>2000</year>;<volume>49</volume>(<issue>6</issue>):<fpage>1006</fpage>&#x02013;<lpage>15</lpage>. Epub 2000/06/24. <?supplied-pmid 10866054?><pub-id pub-id-type="pmid">10866054</pub-id></mixed-citation></ref><ref id="pone.0178011.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Ueno</surname><given-names>Y</given-names></name>, <name><surname>Kizaki</surname><given-names>M</given-names></name>, <name><surname>Nakagiri</surname><given-names>R</given-names></name>, <name><surname>Kamiya</surname><given-names>T</given-names></name>, <name><surname>Sumi</surname><given-names>H</given-names></name>, <name><surname>Osawa</surname><given-names>T</given-names></name>. <article-title>Dietary glutathione protects rats from diabetic nephropathy and neuropathy</article-title>. <source>The Journal of nutrition</source>. <year>2002</year>;<volume>132</volume>(<issue>5</issue>):<fpage>897</fpage>&#x02013;<lpage>900</lpage>. Epub 2002/05/02. <?supplied-pmid 11983810?><pub-id pub-id-type="pmid">11983810</pub-id></mixed-citation></ref><ref id="pone.0178011.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Anitha</surname><given-names>M</given-names></name>, <name><surname>Gondha</surname><given-names>C</given-names></name>, <name><surname>Sutliff</surname><given-names>R</given-names></name>, <name><surname>Parsadanian</surname><given-names>A</given-names></name>, <name><surname>Mwangi</surname><given-names>S</given-names></name>, <name><surname>Sitaraman</surname><given-names>SV</given-names></name>, <etal>et al</etal>
<article-title>GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway</article-title>. <source>The Journal of clinical investigation</source>. <year>2006</year>;<volume>116</volume>(<issue>2</issue>):<fpage>344</fpage>&#x02013;<lpage>56</lpage>. Epub 2006/02/03. PubMed Central PMCID: PMC1359053. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI26295">10.1172/JCI26295</ext-link></comment>
<?supplied-pmid 16453021?><pub-id pub-id-type="pmid">16453021</pub-id></mixed-citation></ref><ref id="pone.0178011.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Mizisin</surname><given-names>AP</given-names></name>, <name><surname>Vu</surname><given-names>Y</given-names></name>, <name><surname>Shuff</surname><given-names>M</given-names></name>, <name><surname>Calcutt</surname><given-names>NA</given-names></name>. <article-title>Ciliary neurotrophic factor improves nerve conduction and ameliorates regeneration deficits in diabetic rats</article-title>. <source>Diabetes</source>. <year>2004</year>;<volume>53</volume>(<issue>7</issue>):<fpage>1807</fpage>&#x02013;<lpage>12</lpage>. Epub 2004/06/29. <?supplied-pmid 15220205?><pub-id pub-id-type="pmid">15220205</pub-id></mixed-citation></ref><ref id="pone.0178011.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Sterne</surname><given-names>GD</given-names></name>, <name><surname>Brown</surname><given-names>RA</given-names></name>, <name><surname>Green</surname><given-names>CJ</given-names></name>, <name><surname>Terenghi</surname><given-names>G</given-names></name>. <article-title>Neurotrophin-3 delivered locally via fibronectin mats enhances peripheral nerve regeneration</article-title>. <source>The European journal of neuroscience</source>. <year>1997</year>;<volume>9</volume>(<issue>7</issue>):<fpage>1388</fpage>&#x02013;<lpage>96</lpage>. Epub 1997/07/01. <?supplied-pmid 9240396?><pub-id pub-id-type="pmid">9240396</pub-id></mixed-citation></ref><ref id="pone.0178011.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Schratzberger</surname><given-names>P</given-names></name>, <name><surname>Walter</surname><given-names>DH</given-names></name>, <name><surname>Rittig</surname><given-names>K</given-names></name>, <name><surname>Bahlmann</surname><given-names>FH</given-names></name>, <name><surname>Pola</surname><given-names>R</given-names></name>, <name><surname>Curry</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Reversal of experimental diabetic neuropathy by VEGF gene transfer</article-title>. <source>The Journal of clinical investigation</source>. <year>2001</year>;<volume>107</volume>(<issue>9</issue>):<fpage>1083</fpage>&#x02013;<lpage>92</lpage>. Epub 2001/05/09. PubMed Central PMCID: PMC209283. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI12188">10.1172/JCI12188</ext-link></comment>
<?supplied-pmid 11342572?><pub-id pub-id-type="pmid">11342572</pub-id></mixed-citation></ref><ref id="pone.0178011.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Nadeem</surname><given-names>L</given-names></name>, <name><surname>Xu</surname><given-names>G</given-names></name>. <article-title>Beneficial effect of TNF-alpha inhibition on diabetic peripheral neuropathy</article-title>. <source>Journal of neuroinflammation</source>. <year>2013</year>;<volume>10</volume>:<fpage>69</fpage> Epub 2013/06/06. PubMed Central PMCID: PMC3679954. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1742-2094-10-69">10.1186/1742-2094-10-69</ext-link></comment>
<?supplied-pmid 23735240?><pub-id pub-id-type="pmid">23735240</pub-id></mixed-citation></ref><ref id="pone.0178011.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Matsunaga</surname><given-names>A</given-names></name>, <name><surname>Kawamoto</surname><given-names>M</given-names></name>, <name><surname>Shiraishi</surname><given-names>S</given-names></name>, <name><surname>Yasuda</surname><given-names>T</given-names></name>, <name><surname>Kajiyama</surname><given-names>S</given-names></name>, <name><surname>Kurita</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats</article-title>. <source>European journal of pharmacology</source>. <year>2007</year>;<volume>554</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>7</lpage>. Epub 2006/11/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejphar.2006.09.072">10.1016/j.ejphar.2006.09.072</ext-link></comment>
<?supplied-pmid 17112505?><pub-id pub-id-type="pmid">17112505</pub-id></mixed-citation></ref><ref id="pone.0178011.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Apfel</surname><given-names>SC</given-names></name>. <article-title>Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?</article-title>
<source>International review of neurobiology</source>. <year>2002</year>;<volume>50</volume>:<fpage>393</fpage>&#x02013;<lpage>413</lpage>. Epub 2002/08/30. <?supplied-pmid 12198818?><pub-id pub-id-type="pmid">12198818</pub-id></mixed-citation></ref><ref id="pone.0178011.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Veves</surname><given-names>A</given-names></name>, <name><surname>King</surname><given-names>GL</given-names></name>. <article-title>Can VEGF reverse diabetic neuropathy in human subjects?</article-title>
<source>The Journal of clinical investigation</source>. <year>2001</year>;<volume>107</volume>(<issue>10</issue>):<fpage>1215</fpage>&#x02013;<lpage>8</lpage>. Epub 2001/05/26. PubMed Central PMCID: PMC209306. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI13038">10.1172/JCI13038</ext-link></comment>
<?supplied-pmid 11375408?><pub-id pub-id-type="pmid">11375408</pub-id></mixed-citation></ref><ref id="pone.0178011.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Albers</surname><given-names>JW</given-names></name>, <name><surname>Pop-Busui</surname><given-names>R</given-names></name>. <article-title>Diabetic neuropathy: mechanisms, emerging treatments, and subtypes</article-title>. <source>Current neurology and neuroscience reports</source>. <year>2014</year>;<volume>14</volume>(<issue>8</issue>):<fpage>473</fpage> Epub 2014/06/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11910-014-0473-5">10.1007/s11910-014-0473-5</ext-link></comment>
<?supplied-pmid 24954624?><pub-id pub-id-type="pmid">24954624</pub-id></mixed-citation></ref><ref id="pone.0178011.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Biancone</surname><given-names>L</given-names></name>, <name><surname>Bruno</surname><given-names>S</given-names></name>, <name><surname>Deregibus</surname><given-names>MC</given-names></name>, <name><surname>Tetta</surname><given-names>C</given-names></name>, <name><surname>Camussi</surname><given-names>G</given-names></name>. <article-title>Therapeutic potential of mesenchymal stem cell-derived microvesicles</article-title>. <source>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association&#x02014;European Renal Association</source>. <year>2012</year>;<volume>27</volume>(<issue>8</issue>):<fpage>3037</fpage>&#x02013;<lpage>42</lpage>. Epub 2012/08/02.</mixed-citation></ref><ref id="pone.0178011.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Howland</surname><given-names>MA</given-names></name>. <article-title>Risks of parenteral deferoxamine for acute iron poisoning</article-title>. <source>Journal of toxicology Clinical toxicology</source>. <year>1996</year>;<volume>34</volume>(<issue>5</issue>):<fpage>491</fpage>&#x02013;<lpage>7</lpage>. Epub 1996/01/01. <?supplied-pmid 8800186?><pub-id pub-id-type="pmid">8800186</pub-id></mixed-citation></ref><ref id="pone.0178011.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Joyce</surname><given-names>N</given-names></name>, <name><surname>Annett</surname><given-names>G</given-names></name>, <name><surname>Wirthlin</surname><given-names>L</given-names></name>, <name><surname>Olson</surname><given-names>S</given-names></name>, <name><surname>Bauer</surname><given-names>G</given-names></name>, <name><surname>Nolta</surname><given-names>JA</given-names></name>. <article-title>Mesenchymal stem cells for the treatment of neurodegenerative disease</article-title>. <source>Regenerative medicine</source>. <year>2010</year>;<volume>5</volume>(<issue>6</issue>):<fpage>933</fpage>&#x02013;<lpage>46</lpage>. Epub 2010/11/19. PubMed Central PMCID: PMC3017479. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2217/rme.10.72">10.2217/rme.10.72</ext-link></comment>
<?supplied-pmid 21082892?><pub-id pub-id-type="pmid">21082892</pub-id></mixed-citation></ref><ref id="pone.0178011.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Thum</surname><given-names>T</given-names></name>, <name><surname>Bauersachs</surname><given-names>J</given-names></name>, <name><surname>Poole-Wilson</surname><given-names>PA</given-names></name>, <name><surname>Volk</surname><given-names>HD</given-names></name>, <name><surname>Anker</surname><given-names>SD</given-names></name>. <article-title>The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle</article-title>. <source>Journal of the American College of Cardiology</source>. <year>2005</year>;<volume>46</volume>(<issue>10</issue>):<fpage>1799</fpage>&#x02013;<lpage>802</lpage>. Epub 2005/11/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2005.07.053">10.1016/j.jacc.2005.07.053</ext-link></comment>
<?supplied-pmid 16286162?><pub-id pub-id-type="pmid">16286162</pub-id></mixed-citation></ref><ref id="pone.0178011.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Trivedi</surname><given-names>P</given-names></name>, <name><surname>Tray</surname><given-names>N</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Nigam</surname><given-names>N</given-names></name>, <name><surname>Gallicano</surname><given-names>GI</given-names></name>. <article-title>Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later</article-title>. <source>Stem cells and development</source>. <year>2010</year>;<volume>19</volume>(<issue>7</issue>):<fpage>1109</fpage>&#x02013;<lpage>20</lpage>. Epub 2010/01/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/scd.2009.0465">10.1089/scd.2009.0465</ext-link></comment>
<?supplied-pmid 20092388?><pub-id pub-id-type="pmid">20092388</pub-id></mixed-citation></ref><ref id="pone.0178011.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Greenberger</surname><given-names>JS</given-names></name>. <article-title>Gene therapy approaches for stem cell protection</article-title>. <source>Gene therapy</source>. <year>2008</year>;<volume>15</volume>(<issue>2</issue>):<fpage>100</fpage>&#x02013;<lpage>8</lpage>. Epub 2007/08/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.gt.3303004">10.1038/sj.gt.3303004</ext-link></comment>
<?supplied-pmid 17700708?><pub-id pub-id-type="pmid">17700708</pub-id></mixed-citation></ref><ref id="pone.0178011.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Sart</surname><given-names>S</given-names></name>, <name><surname>Ma</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>. <article-title>Preconditioning stem cells for in vivo delivery</article-title>. <source>BioResearch open access</source>. <year>2014</year>;<volume>3</volume>(<issue>4</issue>):<fpage>137</fpage>&#x02013;<lpage>49</lpage>. Epub 2014/08/16. PubMed Central PMCID: PMC4120806. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/biores.2014.0012">10.1089/biores.2014.0012</ext-link></comment>
<?supplied-pmid 25126478?><pub-id pub-id-type="pmid">25126478</pub-id></mixed-citation></ref><ref id="pone.0178011.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>M</given-names></name>, <name><surname>Akhtar</surname><given-names>S</given-names></name>, <name><surname>Mohsin</surname><given-names>S</given-names></name>, <name><surname>S</surname><given-names>NK</given-names></name>, <name><surname>Riazuddin</surname><given-names>S</given-names></name>. <article-title>Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells</article-title>. <source>Stem cells and development</source>. <year>2011</year>;<volume>20</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>75</lpage>. Epub 2010/05/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/scd.2009.0397">10.1089/scd.2009.0397</ext-link></comment>
<?supplied-pmid 20446810?><pub-id pub-id-type="pmid">20446810</pub-id></mixed-citation></ref><ref id="pone.0178011.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Keats</surname><given-names>E</given-names></name>, <name><surname>Khan</surname><given-names>ZA</given-names></name>. <article-title>Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose</article-title>. <source>PloS one</source>. <year>2012</year>;<volume>7</volume>(<issue>6</issue>):<fpage>e38752</fpage> Epub 2012/06/16. PubMed Central PMCID: PMC3368917. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0038752">10.1371/journal.pone.0038752</ext-link></comment>
<?supplied-pmid 22701703?><pub-id pub-id-type="pmid">22701703</pub-id></mixed-citation></ref></ref-list></back></article>